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Abstract
Frontotemporal dementia (FTD) is a devastating neurodegenerative disease
characterized by a rapid decline in behavioural, language, and motor abilities. Advances in the
understanding of FTD genetics and pathophysiology, and the subsequent development of novel
disease modifying treatments have highlighted the need for tools to assess their efficacy. While
structural magnetic resonance imaging (MRI) and functional imaging with
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F-

flurodeoxyglucose (FDG) positron emission tomography (PET) are used for clinical diagnosis,
structural changes are subtle at the early stages and PET imaging is expensive and access
limited. Given the coupling of cerebral blood flow (CBF) to energy metabolism, an attractive
alternative is the MRI perfusion technique arterial spin labeling (ASL). Unlike PET, ASL is
completely non-invasive, which is ideal for mapping longitudinal changes in brain function.
However, inconsistent results across FTD studies highlight the need to optimize ASL,
particularly given that the quality of CBF images is sensitive to the imaging parameters.
Accordingly, this thesis investigated the potential of ASL for the detection of longitudinal
perfusion changes associated with FTD and differential diagnosis of FTD subtypes.
To evaluate the sensitivity of ASL, CBF measurements from ASL were compared to
PET with radiolabeled water (15O-water), the gold-standard for imaging CBF. To avoid arterial
sampling, in Study I, I developed and validated a non-invasive PET/MR approach (i.e.
PMRFlow) to quantify perfusion by

15

O-water using a porcine model. Excellent agreement

was found when compared to PET-only measurements (R2 = 0.9, slope = 0.88) over a flow
range from 30 to 100 ml/100g/min. In Study II, I evaluated the sensitivity of ASL relative to
15

O-water for identifying regional hypoperfusion. While

15

O-water showed superior

sensitivity, ASL was also able to identify regional hypoperfusion specific to FTD subtypes
(sensitivity = 70%, specificity = 78%). In Study III, I characterized the longitudinal
reproducibility and reliability of ASL using optimized sequence parameters. Good agreement
of repeat measures (month-separated) was found in both patients (CV = 16.3%, ICC = 0.62)
and controls (CV = 13.9%, ICC = 0.62). Additionally, with a post labeling delay of 2s, transit
time errors were not a significant source of error.

i

In capitalizing on the unique features of PET/MR imaging, most notably the ability to
simultaneously acquire PET and MRI-based perfusion, this thesis demonstrates the utility of
ASL and supports its use in longitudinal studies of FTD.
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Summary for Lay Audience
Frontotemporal dementia (FTD) is a debilitating neurodegenerative disease with no
known cure. Recent advancements in potential symptomatic and disease modifying therapies,
highlight the need for imaging biomarkers to distinguish FTD subtypes and evaluate the
efficacy of novel therapies. Considering that brain perfusion is an early marker of
neurodegeneration, perfusion MRI technique arterial spin labeling (ASL) is an attractive
approach for studying the natural disease progression to identify clinical endpoints. Ultimately,
this could allow for earlier intervention, and provide a means to track changes in response to
novel therapies. However, inconsistent results across FTD studies highlight the need to
optimize ASL, particularly given that it is well known that the quality of brain perfusion images
are sensitive to the chosen imaging parameters.
The objective of this thesis was to explore the role of ASL in differential diagnosis and
longitudinal monitoring of FTD by: developing and validating PMRFlow, a non-invasive
approach for measuring perfusion by the gold standard method, positron emission tomography
(PET) with radiolabeled water (15O-water); optimizing ASL imaging parameters by a direct
comparison to the aforementioned non-invasive approach for measuring perfusion by 15Owater PET; evaluating the sensitivity of ASL for detecting disease-related changes in perfusion
relative to 15O-water PET; and evaluating its longitudinal reproducibility and reliability. In
capitalizing on the unique features of PET/MR imaging, most notably the ability to
simultaneously acquire PET- and MRI-based perfusion images, this thesis demonstrates the
utility of ASL and supports its use as a biomarker in FTD.
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Chapter 1

1

Introduction

1.1 Clinical Motivation: Dementia
Dementia refers to a class of brain disorders associated with progressive cognitive
loss sufficient to disrupt activities of daily living. It is a global healthcare issue, affecting
47 million people worldwide including more than 747,000 Canadians [1]. In the absence
of effective prevention and treatment options, it is estimated that disease prevalence will
triple over the next few decades. While most dementia cases are late onset (65+), a
proportion of individuals develop symptoms as early as 35 years of age [2,3]. For many,
this is during the prime of their lives when they have responsibilities to their families and
in their careers. Dementia not only has a significant impact on the individuals who are
affected, but is also associated with high rates of emotional and financial burden for
caregivers [4]. Symptoms of dementia are gradual, persistent, and progressive; although
individuals are able to live independently in the early stages, as symptoms progress, care
needs intensify, eventually leading to the requirement for round-the-clock assistance.
These sobering facts demonstrate the urgent need for methods to accurately diagnose,
monitor disease progression, and develop potential interventions.
The clinical syndrome of dementia can be due to a variety of pathophysiological
processes and is associated with brain damage to specific regions of the brain. Alzheimer’s
disease (AD), the most common cause of dementia [5], is associated with an abnormal
accumulation of amyloid and tau proteins. These proteins clump together to form plaques
and neurofibrillary tangles that collect between neurons and impede healthy
communication between cells [6]. Clinically, it presents with memory loss (e.g. poor recall,
losing items), aphasia, and impaired visuospatial and executive function. Vascular
dementia (VD) arises from damage to the cerebral vasculature, such as a blockage or
narrowing of the vessels, that reduces regional perfusion. This results in a shortage of
nutrients and oxygen required for the brain to continue functioning normally. While
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symptoms of VD vary based on the regions affected, most cases include: problems with
short term memory, trouble concentrating, hallucinations, and impaired coordination and
balance [7]. Lewy body dementia (LBD) is characterized by abnormal deposits of alphasynuclein protein, also known as Lewy bodies. This affects the brain's ability to produce
acetylcholine, which is associated with memory and learning, and dopamine, which is
associated with movement, mood, and sleeping. Characteristic features include
spontaneous parkinsonism, visual hallucinations, as well as a disproportionate deficit
in attentional, executive function, and visual processing relative to memory and naming
[8]. Frontotemporal dementia (FTD), which is the focus of this thesis, is a rare type of
dementia caused by damage to the cells in the frontal and temporal lobes of the brain. Most
cases of FTD can be characterized by an accumulation of either hyper-phosphorylated tau
protein, transactive response DNA-binding protein 43 (TDP-43), or the FET protein family
(Fused in sarcoma (FUS), Ewing’s sarcoma (EWS), and TATA-binding protein-associated
factor 15 (TAF15)) [9]. While the clinical symptoms of FTD are heterogeneous, the core
features involve behavioural, language, and movement disturbances.

1.2 Clinical Focus: Frontotemporal Dementia
Driven by the economic impact, and the clear unmet need for strategies to diagnose
and treat FTD, the work presented in this thesis focuses on FTD. Compared to AD, FTD
affects people at a younger age, cognitive decline is more rapid, and the symptoms more
heterogeneous [10,11].
FTD is a rare disorder that accounts for 9.1% of all dementia cases [12].
Approximately 30% of presenile dementia cases are diagnosed as FTD, making it the one
of the most common forms of early onset dementia [13]. The true prevalence of FTD is
likely underestimated due to the lack of expertise among primary care physicians [14] and
the lack of validated biomarkers for differential diagnosis [15]. In a neuropathological
study it was estimated that patients were not correctly diagnosed in up to 34% of FTD cases
due to non-referral by the primary care specialist or misdiagnosis [16]. Where most types
of dementia affect people above 65, the mean age of symptom onset is 58 [17] and cases
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as young as 35 years have been reported [2,3]. Since dementia care networks and services
are tailored to older patients with different family and social needs, many patients have
difficulty accessing relevant support [18]. Furthermore, as a direct result of the disease,
individuals who are in their peak earning years and have dependent children, must leave
the workforce. Considering the financial loss resulting from the departure of both patients
and caregivers from the labor force, it comes as no surprise that the economic impact of
FTD has been estimated to be approximately twice that reported for AD [19,20].
Patients with FTD typically show a more rapid cognitive and functional decline in
comparison to AD [21]. On average, individuals with FTD were institutionalized within 5
years of symptom onset [22]. The rate at which FTD progresses varies greatly from person
to person, with life expectancy from symptom onset ranging between 3 - 14 years [10].
Median survival from diagnosis is estimated to be 7 - 13 years in clinical cohorts and 6 - 8
years in neuropathology series [23]. Early studies have suggested shorter survival in FTD
compared to AD [21,24]; however, a recent meta-analysis study demonstrated comparable
median survival rates between the two conditions [25].
In the absence of definitive biomarkers, diagnosis of FTD is based on the
identification of clinical symptoms. Early differential diagnosis of FTD remains a
challenge due to the heterogeneity of clinical presentation both within and between FTD
subtypes, as well as the overlap of symptoms with other diseases [26]. Patients with FTD
are commonly misdiagnosed as having AD or a psychiatric disorder such as schizophrenia,
which is likely related to the progressive nature, shared symptoms, and atypical
manifestations of dementia syndromes [27–29]. This contributes to the significant delay,
sometimes as long as 3 to 4 years, before patients receive an accurate diagnosis [22,26,30].
Since there is no cure, early and accurate diagnosis is especially critical for timely inclusion
in clinical trials, the development of novel disease modifying therapies, and to give family
and caregivers time seek supportive resources. Furthermore, since therapeutic approaches
used to manage symptoms vary, it reduces potential side effects resulting from unnecessary
treatments.
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Age and family history are leading risk factors for neurodegenerative diseases
[31,32]. While the majority of FTD cases are sporadic (no known cause), a family history
is present in approximately 30 - 50% of patients, and an autosomal dominant inheritance
pattern in 10 – 15% of patients [32]. Over 80% of autosomal dominant familial cases are
associated with mutations in chromosome 9 open reading frame 72 (C9orf72),
microtubule-associated protein tau (MAPT), and progranulin (PGRN) [33]. Each mutation
has a distinct pattern of atrophy: C9orf72 mutation carriers show relatively widespread
atrophy including posterior regions[34], MAPT is commonly associated with atrophy in
the anterior medial temporal lobes [35], and PGRN is associated with asymmetric atrophy
in the frontal, temporal and parietal lobes [36,37]. Although familial and sporadic cases
arise from different pathologies, clinical symptoms are similar. Studying pre-symptomatic
mutation carriers provides insight into the earlier stages of disease processes, where
patients are more responsive to treatment and neurological damage is potentially reversible
[38].

1.3 Frontotemporal Dementia Definition
Frontotemporal dementia (FTD) is an umbrella term for a clinically and
neuropathologically heterogeneous group of neurodegenerative brain disorders that present
with insidious onset of behavioural changes, loss of word and object knowledge and
aphasia [39]. Based on the predominant presenting symptoms, FTD can be broadly grouped
as; the behavioural variant (bvFTD) and the primary progressive aphasias (PPA). There are
also related disorders including progressive supranuclear palsy (PSP) syndrome and
corticobasal syndrome (CBS), which share features of FTD. Accurate diagnosis remains a
challenge due to the heterogeneity of the presentation and the convergence of phenotypes
as the disease progresses [9].
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1.4 Frontotemporal Dementia Subtypes
1.4.1

Behavioural Variant

The behavioural variant of FTD is the most common of the FTD subtypes, accounting
for 60% of all cases [17]. The hallmarks of bvFTD are insidious onset of personality
changes, social conduct, and behavioural abnormalities. While there is marked
heterogeneity of the clinical presentation of bvFTD, depending on which brain regions are
most affected, the core symptoms include: behavioural disinhibition, apathy or inertia, loss
of sympathy or empathy, perseverative or compulsive behaviour, hyperorality and dietary
changes, as well as executive deficits with relative sparing of memory and visuospatial
functions [40]. Imaging findings include atrophy, hypometabolism, or hypoperfusion of
the frontal and anterior temporal lobes [40].

1.4.2

Primary Progressive Aphasia

The primary progressive aphasias are a group of disorders that are characterized by
a gradual loss of the ability to speak, read, write, and comprehend spoken language. The
three main variants are the semantic variant of FTD (svFTD), non-fluent primary
progressive aphasia (nfPPA), and the logopenic variant (lvPPA) [41].
Individuals with svFTD typically present with problems naming and understanding
word and object meaning as well as recognizing faces. Other language skills such as
producing speech and repeating phrases are unaffected. During the early stages speech
remains fluent; however, speech becomes vague and has less substantive content with
disease progression [3]. Patients are able to understand high-frequency words, but may
experience challenges comprehending low-frequency words [41]. Imaging to support
diagnosis is associated with atrophy in the anterior temporal lobes. Although the primary
presentation is language deficits, behavioural changes may occur as the disease progresses
[42].
Criteria for a diagnosis of nfPPA includes agrammatism in language production,
slow labored speech production, and phonemic errors. Individuals may omit grammatical
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words, use word endings and tenses incorrectly, and mix up the order of words in sentences
while word comprehension is preserved [41]. With progression, widespread motor
symptoms, such as difficulty swallowing and apraxia of speech (the inability to form words
with the lips and tongue) become apparent. Imaging features include prominent left
posterior fronto-insular atrophy, hypometabolism or hypoperfusion [41].
Logopenic primary progressive aphasia is a recently identified variant of PPA. The
core features of lvPPA are difficulty with word retrieval and sentence repetition [41].
Supporting features include phonological errors in speech and preservation of motor
speech. In contrast to svFTD, patients show less severe lexical retrieval and unlike nfPPA
simple speech is fluent with no agrammatism and limited sound distortions [43]. Imaging
shows abnormalities in the left posterior temporal lobe, supramarginal and angular gyri
[43].

1.4.3

Related Disorders

Progressive supranuclear palsy (PSP) and corticobasal syndromes (CBS) are FTD
related disorders that primarily affect movement. Many of the symptoms of PSP and CBS
resemble Parkinson’s disease; however, neither patient group responds to levodopa (i.e.
dopamine replacement therapy), a pharmaceutical used to treat symptoms of Parkinson’s
disease [44].
PSP is the most commonly diagnosed of the movement disorders [44]. The core
features required for a diagnosis of PSP are ocular motor dysfunction, postural instability,
akinesia, and cognitive dysfunction [45]. Ocular motor dysfunction is manifested as
supranuclear palsy, which refers to the impairment of voluntary eye movements (i.e.
vertical saccades), while involuntary eye movements, such as the vestibulo-ocular reflex,
are preserved. In addition, patients have limited downgaze and report difficulty reading.
Cognitive features include decreased verbal fluency and bradyphrenia (slowed thinking
and processing of information). In the later stages of the disease patients may develop
behavioural and language deficits common to bvFTD and PPA [46,47]. Imaging findings

7

include symmetric midbrain and peduncle atrophy or hypometabolism [45]. On sagittal
magnetic resonance (MR) images, the midbrain has a characteristic hummingbird shape.
Classical presentation of CBS includes progressive asymmetric limb rigidity, limb
dystonia (involuntary muscle contractions resulting in repetitive twisting motions),
myoclonus (brief involuntary twisting), and two of orobuccal or limb apraxia (inability to
make precise voluntary motions), cortical sensory deficit (loss of sensation), and alien limb
phenomena (involuntary limb motion accompanied by estrangement from the limb)
[48,49]. The majority of cases show apraxia in an upper limb, followed by involvement of
the ipsilateral or contralateral lower limb several years later [49]. Similar to PSP, patients
may also present with symptoms of bvFTD and PPA in the later stages [46,50]. Imaging
findings include asymmetric atrophy in the fronto-parietal regions predominantly
contralateral to the affected side, basal ganglia, and cerebral peduncles [49].

1.5 Diagnostic Approaches: Strategies and Challenges
Early differential diagnosis is important for patients to understand their symptoms
and for families to develop a long-term care plan. Since there is no cure, it also allows for
timely inclusion in clinical trials toward the development of novel therapies. Differential
diagnosis based on clinical symptoms alone remains a challenge since the initial symptoms
differ based on the clinical syndrome and furthermore, initial symptoms are not consistent
within subtypes [51]. This is reflected in the relatively long diagnostic latency (3 – 4 years)
between symptom onset and the correct diagnosis [26].
Due to uncertainty in the relationship between the neuropathological findings and
clinical manifestation a typically stepwise or probabilistic diagnosis is provided [42].
Possible FTD represents the earlier stages in which neuropsychological testing in highfunctioning patients may not reveal executive deficits or neuroimaging does not show
atrophy or regional dysfunction. Probable FTD exhibits significant functional decline
including the loss of instrumental and basic activities of daily living as indicated by care
givers or functional questionnaire. Definite FTD is characterized by meeting criteria for
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probable or possible FTD and the presence of a pathogen or histopathological evidence.
Previously, definite FTD was reserved for cases that were confirmed by biopsy and/or
autopsy, but with the increased knowledge of proteinopathy and pathogenic mutations this
is no longer the case [52].

1.6 Assessment of Symptoms
Diagnosis of FTD requires a thorough medical history of the patient,
neuropsychometric evaluation, and neurological examination. Medical history including a
recent history from an informant or caregiver is key to ascertaining a diagnosis since
patients show loss of insight. Reported behavioural changes are often unspecific and could
suggest psychiatric impairment rather than neurodegeneration [52]. Neuropsychological
evaluation (e.g., Addenbrooke's Cognitive Examination (ACE) [53], Neuropsychiatric
Inventory (NPI) [54]) involves pencil and paper tests and interviews to identify patterns of
cognitive loss. This is particularly useful for assessing cognitive deficits that may not be
apparent in everyday life and furthermore, help discriminate from psychiatric disorders and
other causes of dementia [55,56]. Neurological examination involves a detailed assessment
of physical (motor function, reflexes, strength etc.) and cognitive (memory, planning,
behaviour, thinking etc.) function by a neurologist. Further consultation with additional
health care specialists, for example speech pathologists for PPA, can be useful to
distinguish more nuanced details.

1.7 Neuroimaging Biomarkers
The classical role of neuroimaging is to rule out treatable causes of dementia such as
hematomas, brain tumors, strokes, and abscesses, as well as to provide evidence to support
the clinical diagnosis of FTD [57]. More recently, neuroimaging measures have been
explored for use as endpoints in clinical trials to replace the more traditional clinical
assessments of cognition and behaviour, which are inherently variable over time and across
examiners [58]. Compared to cognitive scales, neuroimaging measures have greater
statistical power, which translates into shorter trials and smaller sample sizes [59]. This is
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particularly beneficial in FTD given the rarity of the disease and the associated challenges
with recruitment.

1.7.1

Structural Imaging

In subjects with suspected dementia, anatomical imaging with magnetic resonance
imaging (MRI) or computerized tomography (CT) is performed during the initial
assessment to detect masses, vascular lesions, and hemorrhage [60]. In addition, the
presence of regional atrophy is used to support the diagnosis of FTD [40,61,62]. Although
CT is more cost effective and easily accessible, the improved soft tissue contrast of MRI
allows for a more detailed evaluation of cortical atrophy and vascular disease.
Early structural changes are first evident in the insula and temporal cortices, followed
by the frontal and cingulate cortices and later on, the cerebellum [63]. Although there is
considerable variability in regions affected based on the subtype, stage of the disease, and
pathological cause, there is a general consensus regarding the regions affected by each
subtype. The bvFTD is commonly described as having progressive atrophy in the superior
and middle frontal lobe as well as the anterior temporal lobe [64]. The svFTD is
characterized by volume loss in the anterior, middle, and inferior temporal lobes.
Asymmetric atrophy favoring the dominant side, is not uncommon in the early stages
[64,65]. The nfPPA is associated with asymmetric (predominately left-side) inferior
frontal, superior temporal, and insular atrophy [64,65]. The lvPPA shows left posterior
middle/superior temporal lobe and inferior parietal lobe atrophy [66]. Regional atrophy is
most prominent in the brainstem structures and cerebellum in PSP [67]. Finally, atrophy in
CBS involves the basal ganglia, posterior frontal, and parietal regions [67].
In clinical practice, structural images are visually evaluated for atrophy using rating
scales such as the global cortical atrophy scale [68,69], Fazekas’s scale [70], and Scheltens’
medial temporal lobe scale [71]. These techniques have shown good accuracy for
differentiating FTD from controls (sensitivity = 70 – 94%, specificity = 89 – 99%) [72–74]
as well as FTD from AD (sensitivity = 55 – 94%, specificity = 81 – 97%) [72,73,75].
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More recently, automated approaches have been implemented to assess regional
atrophy. Voxel-based morphometry (VBM) uses statistics to identify differences in brain
anatomy between groups, which allows for an unbiased assessment of grey and/or white
matter atrophy on a voxel-by-voxel basis [76]. Since it does not require any a-priori
assumptions concerning affected regions, it provides a more objective assessment than
traditional approaches. VBM has been used differentiate AD and FTD (sensitivity = 72%,
specificity= 67%), FTD from controls (sensitivity = 81%, specificity= 96%)[77] as well as
differentiate patterns of grey-matter across mutation carriers [78].
Histopathological studies report disease-specific damage in AD and FTD; AD is
associated with damage to layer II of the entorhinal cortex whereas FTD layer III and V of
the frontal and temporal lobes are affected in FTD, suggesting that cortical thickness may
be a more specific measure [79,80]. Indeed, cortical thickness has good accuracy for
differentiating, AD from FTD (73 – 83%), and FTD from controls (74 – 94%) [81].
Additionally, measures of cortical thickness have been implemented to distinguish between
clinical subtypes of FTD (sensitivity = 100%, specificity = 69%) [82]. While these
structural changes show promise regarding differential diagnosis of FTD, they occur later
in the disease process, which significantly reduces the changes of early intervention
[26,83,84].

1.7.2

Functional Imaging

The coupling of brain activity, metabolism, and flow allows for the assessment of
neuronal dysfunction with functional imaging techniques. The utility of these approaches
is the ability to detect disease-related changes that antedate detectable atrophy and clinical
symptoms, allowing for earlier diagnosis [85,86].
18

F-fluorodeoxyglucose (FDG) is a glucose analogue where the hydroxyl group is

substituted by a radiolabeled fluorine nucleotide. Like glucose, FDG is taken up in cells as
part of glycolysis. However, the presence of the 18F nucleotide prevents the molecule from
being fully metabolized, effectively trapping the FTD in the cell. As a result, the
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distribution of FDG reflects glucose metabolism. FDG in combination with positron
emission tomography (PET) is an established technique that is commonly used as a
supportive feature in diagnosis, particularly in patients with early and non-specific
symptoms [87]. FDG-PET studies demonstrate high sensitivity and specificity for
differential diagnosis of FTD and AD (sensitivity = 73 – 89%, specificity =78 – 97% )[87–
89], as well as FTD and controls (sensitivity = 79 -89%, specificity = 90.9 – 88.4)[89,90].
Patterns of regional hypometabolism largely resemble atrophy. The bvFTD is
commonly associated with hypometabolism in the orbitofrontal, dorsolateral and medial
prefrontal cortex, and anterior temporal poles [91–93]. Patients with svFTD show
asymmetrical left hemisphere involvement in the entorhinal and perirhinal cortex, inferior
temporal poles, and amygdala [91,94]. The nfPPA shows pronounced hypometabolism in
the left inferior frontal and superior temporal regions [95]. Patients with lvPPA show
distributed left fronto-temporo-parietal hypometabolism, particularly involving lateral
frontal and posterior-lateral temporal lobes, alongside the caudate, posterior cingulate and
precuneus regions [95–97]. The PSP shows reduced metabolism in the ventrolateral frontal
areas, thalamus, caudate and brainstem [98–100]. Finally, CBS patients show highly
asymmetric hypometabolism of frontoparietal areas, striatum, and thalamus contralateral
to the affected side [98–100]. Despite the advantages of FDG-PET, its utility is limited by
the high cost, limited access, and exposure to ionizing radiation.
Arterial spin labeling (ASL) is an MRI technique that uses magnetically labeled
arterial blood water as an endogenous tracer, making it a non-invasive technique, free of
ionizing radiation. Compared to the lengthy setup involved with FDG-PET imaging,
perfusion maps can be generated with a ~5 to 10 minute scan [101]. Regional
hypoperfusion correlates well with regional hypometabolism, demonstrating the strong
potential of ASL as an alternative to FDG-PET [89,93]. In a study involving patients with
autopsy-confirmed diagnosis, ASL identified distinct regions of hypoperfusion in FTD
relative to controls (i.e. prefrontal cortex, inferior frontal cortex, and insula) as well as
patients with AD (inferior frontal cortex, anterior cingulate cortex, and prefrontal cortex)
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[102]. Additionally, ASL is capable of detecting perfusion abnormalities before structural
changes were apparent [103]. More impressive, is its ability to detect disease-related
perfusion abnormalities in the preclinical stages independent of grey-matter atrophy [104–
106]. The sensitivity and specificity of ASL for differentiating FTD and controls is reported
as 67–79% and 62–92% respectively [89,90,107]. For distinguishing between AD and
FTD, these results were 69–83 and 68–93%, respectively. [89,107]. Altogether, these
studies highlight the potential of ASL as a sensitive marker of perfusion deficits in FTD
and the related disorders.

1.8 Treatment Strategies
Currently, there is no curative pharmaceutical agent approved by Health Canada or
the Food and Drug Administration to prevent, cure, or slow the progression of FTD.
Instead, the clinical focus has been on the management of behavioural, cognitive, and
motor symptoms using medications off-label. Unfortunately, many of these therapies lack
evidence from randomized, placebo-controlled clinical trials [108]. Antipsychotics and
antiepileptics have been proposed to manage behavioural symptoms; however, use is
limited due to potential side effects [109–111]. Other reports have indicated that selective
serotonin reuptake inhibitors may be effective [112,113]. While cholinesterase inhibitors
have been explored to manage cognitive deficits, results have been disappointing, with
patients showing no improvement in cognition and worsening impulsivity and disinhibition
[114,115]. To date, there are no effective therapies to manage cognitive symptoms.
Generally, motor symptoms observed in FTD and the related disorders are not alleviated
by dopamine replacement therapies (e.g. levodopa), nevertheless, a few cases of possible
benefit have been reported [116]. Nonpharmaceutical therapies including physical and
occupational therapy for motor symptoms and speech therapy for symptoms associated
with aphasia, apraxia, and dysarthria can help manage the respective symptoms; however,
they do not modify the disease course. Recent advances in the understanding of FTD
pathophysiology and genetics have led to the development of candidate symptomatic and
disease modifying drug therapies [108]. There is great enthusiasm for potential therapies
including anti-tau antibodies, tau aggregation inhibitors, microtubule stabilizers,
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progranulin modulators, and antisense oligonucleotides [117–120]. However, a major
obstacle to clinical trials is the heterogeneity of clinical symptoms, which makes it
challenging to identify treatment effects and outcome measures.

1.9 Longitudinal Neuroimaging Biomarkers
A major challenge in FTD research is the lack of effective strategies for early
diagnosis. FTD disorders are diverse, consisting of a variety of clinical syndromes and
underlying pathophysiologies. While clinical symptoms can be used to differentiate
subtypes in the later stages of the disease, less is known about the presymptomatic stage.
The presymptomatic stage provides an opportunity to study the disease process and
potentially intervene at an earlier stage, where pathological damage is minimal and
potentially reversible. One way to gain such insight is to study the natural disease history;
the progression of a disease without intervention. Given that FTD has a strong genetic
component, with 30 - 50% of familial cases [32], this can be achieved by studying mutation
carriers before symptom onset. Collecting longitudinal data (e.g. cognitive tests, blood
proteins, brain imaging etc.), and assessing the change in these measures, can provide
insight into disease characteristics as well as measures that predict disease procession and
therapeutic effects. These insights can be used as endpoints for clinical trials and,
ultimately, reduce associated delays in diagnosis. Imaging measures have been proposed
as candidate clinical endpoints since they provide an objective assessment of dysfunction
that correlates with clinical measures and are sensitive to the presymptomatic stage of the
disease [121].
To date, most longitudinal studies focus on structural changes using MRI [122–124].
These studies have provided valuable information concerning the differing rates of regional
atrophy and ventricular expansion in familial and sporadic FTD [122,123,125], as well as
across neurodegenerative diseases [125,126]. However, structural changes in the
prodromal phase can be subtle, reducing the possibility for early intervention [127].
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FDG-PET has been proposed as a suitable modality for early differential diagnosis
of FTD. In mutation carriers, studies have demonstrated its ability to detect
neurodegeneration before atrophy becomes apparent on structural images [128].
Furthermore, FDG-PET has been implemented to study the patterns and speed of
pathological spread in bvFTD [91,129] and svFTD [129,130] and nfPPA [129]. Although
these studies demonstrate the potential of FDG-PET as an early marker of
neurodegeneration, PET imaging is expensive and access limited.
Arterial spin labeling is an attractive technique for longitudinal imaging since it is
both non-invasive and quantitative. The quantitative quality allows for the assessment of
longitudinal changes; however, the detectable perfusion change will depend on the
variability between scans. Several studies have assessed variability in regions of interest
(ROIs). The coefficient of variation (CV) in young healthy over various time frames (i.e.
hours [131–133], weeks [134–136], and months [137]) was typically less than 15%. A
study assessing reproducibility over different scan intervals demonstrated that compared
to scans acquired on the same day, longer scan intervals (> 1 week) showed greater
variability since it is affected by additional sources of variance, namely, repositioning
errors and physiological variation in blood flow. Mutsaerts et al. demonstrated that the
variance in grey-matter perfusion between sessions within a single scanner vendor (CV=
7.1 – 7.5%) and between scanner vendors (CV = 8.9%) are comparable [138]. This
suggests that similar perfusion images can be obtained across scanner vendors and
demonstrates the potential for data-pooling in multi-center clinical trials [138,139].
Reproducibility in clinical populations were within a similar range; cerebral blood flow
(CBF) data acquired in dementia patients (AD and FTD) during sessions separated by ~ 4
weeks were within 10.9% of each other [140]; data acquired ~6 weeks apart in adult Latinx
participants at risk for vascular disease had a CV = 7% [141]. While these studies provide
important insights into the variability of regional perfusion, regions affected by the disease
may not be known a priori. In this case, a voxel-by-voxel approach is more valuable.
Beyond our previous study that showed within- and between-session variability of 9.1 and
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10.0% [136], respectively, in young healthy volunteers, few studies have investigated
voxel-by-voxel variability.
It is typically accepted that perfusion and metabolism are coupled in FTD since
unlike AD, the vascular component is not as significant [142]. Consequently, there is a
strong association between regional hypoperfusion and hypometabolism, suggesting that
similar diagnostic information can be extracted from these imaging techniques. However,
results of studies evaluating the utility of ASL have been mixed, as indicated by
inconsistencies in terms of the sensitivity of ASL to dementia-related perfusion
abnormalities. Some studies have reported similar patterns of regional hypometabolism
and hypoperfusion as acquired by FDG-PET and ASL, respectively, in FTD [89,93,143],
Alzheimer’s disease, and mild cognitive impairment [144–146]. Fällmar et al. reported that
ASL had better specificity [147], while others reported reduced classification accuracy
[148,149] and no added benefit [150]. This is likely related to variations in ASL techniques,
imaging parameters, and patient populations.
For example, Tosun et al. evaluated the sensitivity of ASL (using a pulsed ASL
sequence and post labeling delay (PLD) of 1800 ms) and FDG-PET for differentiating
patients with AD (n = 32) and bvFTD/svFTD (n = 28). Verfaillie et al. assessed the overlap
of regional deficits identified by ASL (pseudo-continuous ASL (pCASL) with PLD of
2000ms) and FDG-PET in patients with bvFTD (n = 12) and AD (n = 18). Fällmar used
visual assessments of statistical maps (z-score) generated using CBF by ASL and FDGPET in patients with AD (n = 25) and bvFTD (n = 20). Two ASL sequences were used; (1)
3D pCASL with PLD = 2000 ms and (2) 2D pCASL with PLD = 1600 ms and labeling
duration (LD) = 1650ms. Anazodo et al. used visual assessments and statistical parametric
mapping to evaluate the sensitivity and specificity of simultaneously acquired ASL (3D
pCASL, PLD = 1500ms and LD = 1500 ms) and FDG-PET data in patients with bvFTD (n
= 7), bvFTD+nfPPA (n = 1), and svFTD (n = 1). Bron et al. used a 3D pCASL sequence
with PLD = 1530 ms and LD = 1450 ms in patients with; probable AD (n = 8), possible
AD (n = 3), AD/FTD (n = 9), possible FTD (n = 8), and probable FTD (n = 3). The
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discrepancy in findings across these studies demonstrate the importance of selecting
optimal parameters to reliably image perfusion. Although ASL shows promise, its
sensitivity to the chosen labeling parameters can reduce its ability to detect and monitor
perfusion abnormalities. This highlights the need for validation studies to evaluate the
sensitivity of ASL for detecting perfusion abnormalities and monitoring longitudinal
changes.

1.10 Imaging Perfusion
This section summarizes the brain imaging techniques used to quantify perfusion in
this thesis. First, an overview of perfusion imaging by radiolabeled water (15O-water) PET.
Next, phase contrast (PC) MRI, a technique that uses phase information to quantify flow
in large vessels. In this thesis, PC MRI was used to measure global CBF to calibrate 15Owater PET [151]. Finally, ASL, a non-invasive MRI-based perfusion technique.

1.11

15

O-water PET

Oxygen-15 is a short-lived positron emitting isotope that is reacted with hydrogen
gas to produce

15

O-water [152].

15

O-water is the gold standard for quantifying brain

perfusion in humans because it is highly diffusible and is not metabolized. Perfusion
imaging begins with a venous bolus injection of 15O-water. The tracer travels through the
venous circulation to the heart and then to the lungs where the blood is oxygenated. The
oxygenated blood returns to the heart where it is pumped to the rest of the body, including
the brain where annihilation photons are detected by the PET detectors. The regional
accumulation of 15O-water reflects regional perfusion.

1.11.1

Quantification of Cerebral Blood Flow

Quantification of CBF is based on the Kety and Schmidt single compartment model
[153]. This model states that the rate of change of 15O-water concentration in tissue, Ct(t),
is equal to the difference in arterial and venous concentrations:
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𝑑
𝐶 (𝑡) = 𝑓(𝐶𝑎 (𝑡) − 𝐶𝑣 (𝑡))
𝑑𝑡 𝑡

(1.1)

where 𝑓 is CBF in ml/100g/min, Ca(t) the arterial 15O-water concentration and Cv(t)
the
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O-water venous concentration. Because the permeability-surface area product of

water is large relative compared to flow (i.e. a freely diffusible tracer), Ct(t) is assumed to
be at equilibrium with Cv(t) and therefore the latter can be replaced in Eqn. (1.1) by
including the partition coefficient of water (λ):
𝑑
𝑓
𝐶𝑡 (𝑡) = 𝑓𝐶𝑎 (𝑡) − 𝐶𝑡 (𝑡)
𝑑𝑡
𝜆

(1.2)

where λ represents the ratio of the equilibrium water concentration in tissue to blood
which is assumed to be 0.9 g/mL [154]. The analytical solution to Eqn. (1.2) is given by:
𝑡

𝐶𝑡 (𝑡) = 𝑓 ∫ 𝐶𝑎 (𝑢)𝑒 −𝑘2(𝑡−𝑢) 𝑑𝑢

(1.3)

0

where, 𝑘2 = 𝑓 ⁄𝜆. Perfusion can be estimated from Eqn. (1.3) by non-linear least
squares.

1.11.2

Model Considerations

As evident by Eqn. (1.3, determining CBF requires measuring the time-varying
arterial concentration of 15O-water, which is known as the arterial input function (AIF).
This can be performed by sampling blood from a peripheral artery (e.g., the radial artery).
Since the AIF measured at peripheral site is an estimate of that entering the brain, the AIF
must be corrected for the delay between when radioactivity reaches the brain relative to
when it reaches the sampling site and for differences in the shape of the bolus due to
dispersion in the blood vessels (internal dispersion) and sampling system (external
dispersion) [155,156]. Delay correction is typically performed by measuring the difference
in arrival times at the two sites tissue [157]. A dispersion time constant can be included as
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an additional parameter in the fitting routine by modelling dispersion as an monoexponential function.
Equation (1.3) assumes that all radioactivity detected originates from the tissue.
Given that intravascular radioactivity will also contribute to the detected activity, the
equation can be modified as follows:
𝑡

𝐶𝑡 (𝑡) = ∫ 𝐶𝑎 (𝑢)𝑒 −𝑘2(𝑡−𝑢) 𝑑𝑢 + 𝐶𝐵𝑉𝑎 ∙ 𝐶𝑎 (𝑡)𝑑𝑡

(1.4)

0

where, CBVa represents the arterial blood volume, which can be included as a model
parameter. CBVa is approximately 1.1ml/100ml, corresponding to 37% of the total cerebral
blood volume (CBV) [158]. Neglecting Vb can contribute to overestimations (>25%) in
blood flow, particularly in highly vascularized regions [159,160].
The need for arterial sampling to determine the AIF is not only invasive, but prone
to error [156,161] and discourages patients and healthy volunteers from participating in
clinical research. A frequently proposed alternative is to obtain an image-derived input
function (IDIF) from serial PET images. Although this approach has been successfully
validated using large arterial blood pools such as the left ventricle [162,163], and large
vessels such as the aortic segments [164], these structures are not typically within the field
of view for brain imaging. Instead, the intracranial blood vessels which have an average
diameter of 4-5 mm are used [165]. The limited spatial resolution of PET scanners (~ 6mm
[166,167]) relative to the vessel size results in partial volume artifacts that can substantially
alter both the shape and amplitude of the true AIF. Specifically, a “spill-out” effect where
the activity inside the vessels spread beyond its borders, resulting in underestimated
activity, and a “spill-in” effect where activity from the surrounding tissue spills into the
vessel, artificially increasing the activity.
Correcting for these partial volume effects requires knowledge of the geometry of
the artery and the point spread function (PSF) of the imaging system [168]. This can be a
challenge for PET-only scanners due to the lack of an anatomical reference and separately
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acquired structural MRIs are prone to registration errors. A recent study overcame this
obstacle using a hybrid PET/MR scanner for simultaneous PET and MRI acquisitions
[169]. Spill-over effects were addressed by scaling the counts from an early PET image by
the intravascular volume measured by MR angiography, and spill-in minimized by
obtaining the IDIF from an artery further away from the brain. A recent study showed that
these IDIFs correlated well (R = 0.93) with AIFs obtained using arterial sampling [170].
One of the challenges with IDIFs is ensuring sufficient temporal imaging resolution to
accurately capture the fast dynamics of a bolus injection [156,170].
An alternative non-invasive approach for quantifying perfusion is the referencetissue approach. If there is a region with known CBF, then blood flow in any other voxel
or ROI can be determined by relating its time activity data to that of the reference region,
thereby eliminating the need for an AIF or the complexities of extracting the IDIF. This
was first proposed by Mejia et al. who used the whole-brain tissue activity as the reference
region, assuming global perfusion equal to 50 ml/100g/min [171]. Watabe et al. extended
this approach by including whole-brain CBF as an additional fitting parameters in the
analysis of time activity curves from two regions, whole brain and a cluster of voxels with
the top 10% of the highest counts [172]. However, the solution is ill-posed and does not
generate reliable estimates of absolute CBF[173]. Integrated PET/MR imaging can
overcome this issue by acquiring an estimate of global CBF by PC MRI, while collecting
the PET data, which will be discussed further in Chapter 2 [151].
Despite these advances in non-invasive 15O-water approaches for imaging CBF, 15OPET has the disadvantages of requiring an onsite cyclotron due to the short half-life (122
s) and higher cost relative to MRI. These limitations provide motivation for the
development of MRI-based methods for measuring perfusion, such as ASL, that are more
widely accessible.
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1.12 Phase Contrast MRI
Phase contrast is a simple and non-invasive method that uses the phase of an image
to encode the velocity of blood. By measuring the flow in the brain’s feeding arteries, it
can be used to estimate whole brain perfusion. Its ability to quantify absolute perfusion
with good accuracy in a short period of time makes it an attractive technique for clinical
and research applications [174,175]. For example, PC has been used to assess flow in the
intracranial arteries in patients with cerebrovascular disease [176], evaluate cerebral
autoregulation [177], calibrate perfusion by ASL [178], and more recently perfusion [151]
and CMRO2 [179] by PET.
Image contrast is generated using a bipolar gradient (also known as a flow encoding
gradient) to produce a phase change in spins that is linearly proportional to the velocity.
Since the flow encoding gradient has a net zero polarity, stationary spins will accumulate
no additional phase while spins moving in the direction of the gradient will accumulate a
phase proportional to its velocity and direction. Phase shifts are measured in degrees
ranging from 0 to 180, where the peak velocity corresponds to a phase shift of 180 degrees.
The velocity encoding (Venc) characterizes the highest and lowest flow values that can be
detected. To accurately measure velocity, the Venc should be larger than the highest velocity
being measured to avoid aliasing. Although phase unwrapping can be used to correct for
aliased velocities, Venc below one third of the maximum velocity cannot be corrected [180].
Conversely, if the Venc is arbitrarily large, the range of flows will span a limited range of
the phase shift, resulting in reduced signal to noise ratio (SNR).
Gating techniques are used segment the data into several cardiac cycles to improve
the temporal resolution and minimize spatial blurring due to motion. The cardiac cycle is
monitored using a pulse oximeter or an echocardiogram (ECG) and triggers (e.g. peak Rwave or peak systolic pressure) are used to time the acquisition. Prospectively gated
sequences acquire data during a window between R-waves. The following acquisition will
begin once the next trigger is set. The benefit of truncating the data to a constant length is
that it is made insensitive to mild arrhythmia. However, it means that it will not be able to
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capture the data during diastole since data are not sampled during the arrhythmia rejection
window. With retrospective gating, data are recorded over the entire cardiac cycle. During
image reconstruction, triggers are used to retrospectively assign the data to different phases
of the cardiac cycle.
Non-triggered sequences collect signal continuously and produce one image that
represents an average of the signal over the entire cardiac cycle. The advantage of this
approach is that it takes less time since it does not rely on the heart rate to determine when
the data are collected. Second, variability in the heart rate can introduce error - which is
not a factor with non-triggered data. Third, where gated sequences produce a series of
images that span the cardiac cycle, continuous imaging only produces one image. This
means that there are fewer processing steps required to quantify CBF since ROIs only need
to be generated for one image instead of over the entire cardiac cycle. Despite these
advantages, in phantoms, triggered sequences produce flow values which are closer to the
truth with an average difference of 4.9% (non-gated = 8.3%) [174]. In vivo, triggered PC
is more reproducible (CV = 7.1% vs 10.3%), whereas non-triggered sequences tend to
overestimate CBF due to the loss of information (partial volume errors) at the periphery of
the vessel [174].
For precise measurement of flow, the imaging plane should be positioned orthogonal
to the main direction of flow. In the brain, the main vessels that contribute to whole brain
perfusion are the internal carotid and vertebral arteries. Although orthogonal slice
angulation with respect to all 4 vessels can be challenging to achieve in practice, the bias
is negligible if the slice orientation with within 10 degrees of ideal angulation [181]. A
second consideration is the spatial resolution; significant partial volume errors result if the
pixel size is less than one third of the vessel diameter [182]. In practice, spatial resolution
of 0.5 mm is recommended [181]. The PC acquisition yields a phase image containing the
velocity information as well as a magnitude image containing anatomical information.
With gated sequences, PC data are reconstructed into a series of frames representing the
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cardiac cycle. The temporal resolution should be optimized to accurately characterize the
cardiac cycle.

1.12.1

Quantification of Cerebral Blood Flow

To quantify whole brain perfusion, first the mean pixel intensity from the phase
image is converted into velocity (v⊥, in units of cm/s) based on the linear relationship
between the Venc and pixel intensity:
𝑣⊥ = 𝑉enc ⋅

∆ø𝑖
𝜋

−𝑉enc < 𝑣⊥ < 𝑉enc

(1.5)

−𝜋 < ∆ø𝑖 < π
where Venc (cm/s) represents the maximum encoded flow velocity, π (radians) is
maximum value of the range of pixel intensities in the phase image and ∆øi (radians) is the
pixel intensity of the current voxel. Next, whole-brain CBF in ml/100g/min is quantified
by scaling the average intensity by the brain tissue mass:
𝐶𝐵𝐹 =

𝑣⊥ ⋅ 𝐴 ⋅ 60 ⋅ 100
𝜌 ⋅ 𝑇𝐼𝑉

(1.6)

where A is the vessel cross sectional area in cm2, 60 ⋅ 100 converts units of mL/g/s
to mL/100g/min, TIV is the total intracranial volume in mL, and ρ is the tissue density
(1.05 g/mL) [154]. To determine the vessel cross sectional area, ROIs of the arteries of
interest are delineated on the magnitude image and the number of voxels within each ROI
is multiplied by the voxel area in the x/y plane. Total intracranial volume is estimated by
multiplying the number of voxels in a skull stripped mask of an T1-weighted image by the
voxel volume.
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1.13 Arterial Spin Labeling
Arterial spin labeling is a non-invasive perfusion imaging technique that uses
magnetically labeled water as an endogenous tracer [183]. ASL is analogous to 15O-water
PET since they both use water as a means for quantifying perfusion [184]. ASL contrast is
generated using a slab of selective radiofrequency (RF) pulses to invert the longitudinal
magnetization of flowing blood water in the neck region. This “labeled” blood acts as a
bolus of signal that enters the downstream imaging volume. To allow the labeled blood to
reach the tissue, a short delay (i.e. post labeling delay, PLD) is inserted. As the labeled
blood is delivered to the tissue, magnetization is exchanged, resulting in a local change in
the magnetization. This inverted blood signal comprises the ASL label image. Since the
label image contains signal from both static and moving sources, a control image with no
labeling is acquired to account for the former signal contribution. Control and label images
are acquired in interleaved succession. Simple subtraction of the control and labeled image
results in a perfusion weighted or difference image which is directly proportional to the
perfusion [185].

CASL/pCASL
Labeling
Imaging Volume

LD

CASL/pCASL
Labeling Plane

PASL Labeling

Image
Acquisition
PLD

Image
Acquisition

PASL Labeling Slab
PLD

Figure 1.1: Schematic of ASL labeling strategies. Labeling by CASL and
pCASL is characterized by a long labeling duration (i.e. LD) over a
narrow labeling plane whereas PASL labeling is for a shorter duration
over a larger volume of tissue.
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Based on the duration and spatial extent of signal inversion, ASL labeling strategies
are classified as pulsed (PASL), or continuous (CASL) (Figure 1.1). In CASL, arterial
blood is labeled over a 1 - 3 s period as it passes through a narrow (a few millimeters)
labeling plane [186]. In contrast, with PASL, a large volume of tissue (10 - 20 cm) is
labeled using a short (5 - 25 ms) labeling pulse [187]. Compared to PASL, CASL provides
higher SNR because, first, the labeling period is longer giving rise to more signal and
second, there is less signal decay since the labeling plane is closer to the imaging plane
[188]. However, the labeling efficiency of PASL is higher, since unlike CASL, signal
inversion is insensitive to the velocity of blood within the labeling volume [188]. Despite
the improved SNR achieved using CASL, high RF power, which corresponds to high
specific absorption rate, is required to accommodate the long the labeling duration (LD).
In addition, an extra transmission coil is required to transmit the long LD. To address these
limitations, pseudo-continuous ASL (pCASL), the current recommended labeling strategy,
was developed [101,189]. This approach is analogous to CASL, except in place of a
continuous label, a series of short RF pulses (1 pulses/ms) are applied [189]. PCASL is
easily implemented on conventional 1.5/3 T MRI scanners and has sufficient SNR, which
has contributed to the quick and widespread adoption of this labeling scheme by the ASL
community.

1.13.1

ASL Signal Modeling

Quantification of tissue perfusion by ASL relies on the principles of tracer kinetics.
The general kinetic model describes the ASL difference signal (ΔM) in terms of the
delivery of the label a(t), and the residual function R(t). The delivery function for the
pCASL labeling scheme is given by:
0
2𝛼M0 −𝐴𝑇𝑇
𝑒 𝑇1𝑎
𝜆

𝑎(t) =
{

0

0 < 𝑡 < 𝐴𝑇𝑇
𝐴𝑇𝑇 ≤ 𝑡 < 𝜏 + 𝐴𝑇𝑇
𝜏 + 𝐴𝑇𝑇 ≤ 𝑡

(1.7)
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where M0 is the equilibrium magnetization, λ is the blood-brain partition coefficient of
water, ATT is the arterial transit time, T1a is the longitudinal relaxation of arterial blood, α
is the labeling efficiency, and τ is the labeling duration. The shape of the delivery function
largely depends on the labeling duration (i.e., how much labeled blood water is created)
and the time taken for the label to reach the tissue (i.e. the ATT). Where the former is a
user set parameter, the latter will vary based on the age and vasculature of the participant
being imaged.
Initially, all the labeled blood is in the tissue; however, the signal decreases over time
due to magnetization relaxation m(t), and the clearance of signal to the venous circulation
r(t). The residue function is expressed as the product of these terms (i.e. R(t) = r(t)⋅m(t)).
The magnetization relaxation is given by:
−𝑡

𝑚(𝑡) = 𝑒 𝑇1𝑡

(1.8)

where, where T1t is the longitudinal relaxation of tissue. The clearance of the label
to the venous circulation is given by:
𝑟(𝑡) = 𝑒

−𝑓𝑡
𝜆

(1.9)

The difference signal is the convolution of the input function with the residual
function. Since T1 decay is quick enough that there is a negligible amount of signal left by
the time it reaches the venous circulation, the residual function can be expressed in terms
of m(t) exclusively. Mathematically,
ΔM = 𝑓 ⋅ 𝑎(𝑡) ∗ 𝑅(𝑡)

(1.10)

For the definition of 𝑎(t) provided by Eqn. (1.7), the solution for ΔM is given by:
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0
2𝛼Mo 𝑓𝑇1𝑎 −𝐴𝑇𝑇
ΔM(t) =
𝑒 𝑇1𝑎
𝜆

1−𝑒

{

0 < 𝑡 < 𝐴𝑇𝑇

−(𝑡−𝐴𝑇𝑇)
𝑇1𝑎

−(𝑡−𝐴𝑇𝑇− 𝜏)
𝑇1𝑎
𝑒

⋅ (1 −

𝐴𝑇𝑇 ≤ 𝑡 < 𝜏 + 𝐴𝑇𝑇 (1.11)
−𝜏
𝑇
𝑒 1𝑎 )

𝜏 + 𝐴𝑇𝑇 ≤ 𝑡

Note, since the magnitude of T1 of tissue and blood are similar, the above model assumes
that T1a ≅ T1t.

1.13.2

Single Delay ASL

With single-delay pCASL (SD-pCASL), perfusion-weighted images are acquired at
a one optimized PLD. It is a robust and straightforward means of obtaining perfusion image
and is accepted as the recommended implementation by the ASL community [101]. To
minimize potential bias due to incomplete delivery, the PLD should be just longer than the
longest ATT. Under these conditions, CBF is given by:
𝑃𝐿𝐷

𝐶𝐵𝐹 =

60 ⋅ 100 ⋅ ΔM𝜆𝑒 𝑇1𝑎
2𝛼Mo 𝑇1𝑎 (1 − 𝑒

−(𝜏+𝑃𝐿𝐷)
𝑇1𝑎
)

(1.12)

where 60 ⋅ 100 converts units of mL/g/s to mL/100g/min, T1a = 1650 ms [190], and
α = 85% [189]. An M0 image can be obtained from a separate acquisition with identical
readout from the control image, but with a long repetition time (TR) (> 5 s) to provide
proton density weighting [101].

1.13.3

Multi-Delay ASL

Single-delay pCASL relies on the assumption that there is complete delivery of the
bolus by the end of the PLD. In older and clinical populations that have lengthy ATT, this
can be challenging to achieve and is considered a major source of error [101,191]. Multidelay sequences circumvent this issue by sampling the ASL signal at a series of PLDs and
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fitting the fractional signal to Equation (1.7). While the major advantage of multi-delay
pCASL is the ability to simultaneously measure ATT and CBF, acquiring of data at
multiple PLDs is time consuming, suffers from lower SNR, and is often contaminated by
intravascular signals [192]. However, since ATT images are fundamentally low resolution
as variations are based on large vascular territories, an alternative approach is to acquire
data with a relatively low spatial resolution [192]. By increasing the voxel size, the time
required to acquire ATT images is greatly reduced and the SNR improved.
More recently, Hadamard encoded (or time-encoded) sequences with improved SNR
and temporal efficiency have been developed [193,194]. As shown in Figure 1.2, with
Hadamard-encoded ASL, the label bolus is divided into N uniquely encoded label and
control sub-boluses where their ordering corresponds to an NxN Hadamard matrix
[193,194]. N is typically between 8 and 12. Since the sub-boli are generated consecutively,
each sub-bolus corresponds to a different PLD. Images at each PLDs are extracted by a
linear combination of the images. For example, in Figure 1.2, by combining: Acquisition
1 – Acquisition 2 – Acquisition 3 + Acquisition 4 – Acquisition 5 + Acquisition 6 +
Acquisition 7 – Acquisition 8, all sub-boli except the 7th sub-boli (i.e. SBL 7) are cancelled
out. Thus, the corresponding image is analogous to a ΔM image with PLD = Effective
PLD1 and LD = sub-boli length. The extracted perfusion-weighted images are analogous
to the result of a conventional multi-delay experiment, whereby, CBF and ATT are
quantified by parameter fitting of Equation (1.7). Two common variations of Hadamard
encoded ASL are conventional time-encoding (conv_TE-pCASL), where the sub-boluses
are divided into blocks of equal length, and free-lunch time-encoding (FL_TE-pCASL),
where the labeling period is similar in length to the SD-pCASL sequence; however, the
traditional PLD is replaced with time-encoding blocks.
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Effective PLD 3
Effective PLD 2
Effective PLD 1
Acquisition 1
Acquisition 2
Acquisition 3
Acquisition 4
Acquisition 5
Acquisition 6
Acquisition 7
Acquisition 8
SBL 1

SBL 2

SBL 3

SBL 4
Label

SBL 5
Control

SBL 6

SBL 7

Readout

Figure 1.2: Schematic of Hadamard encoded matrix for application of
time encoded ASL. Labeling is split into 7 labeling (dark blue) and
control (light blue) sub-boli (SBL) and an additional delay between the
last sub-boli and the readout module. The 8 acquisitions are linearly
combined to compute images at different effective PLDs.

Compared to conventional multi-delay ASL, Hadamard encoded sequences are
roughly twice as time efficient since half the number of measurements are required to
obtain the same number of images [193,195]. Whereas separate control and label images
are acquired with multi-delay sequences, control and label sub-boluses are interleaved with
Hadamard-encoded ASL. In addition, Hadamard-encoded ASL has a higher SNR since all
encoded images are used to compute the decoded image at the respective PLD
[193,195,196]. This is in comparison to the conventional multi-delay sequence where only
two images are used.
A major challenge with Hadamard encoding is motion artefacts. Hadamard-encoded
ASL has a longer temporal footprint; all 8 - 12 acquisitions are required to generate the
perfusion-weighted images. In comparison, only two acquisitions are required for the
conventional multi-delay sequence. Since all acquisitions are used in the decoding step,
any artifact or motion will affect all decoded images. This is particularly problematic in
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clinical populations who may be less compliant. Walsh-ordering of the Hadamard matrix
can be implemented to allow for the recovery of data at a lower temporal resolution (i.e.
fewer encoding steps) [193,195].

1.13.4

Confounds

The magnitude of the ASL difference signal depends on blood flow, the lifetime of
the labeled blood water (i.e. T1a), and the amount of time taken for the label to reach the
imaging voxel (i.e. ATT). The SNR of ASL is inherently low since the labeled arterial
blood only reduces the brain signal by ~1%. Additionally, the tracer lifetime and the
average ATT are similar in length. To improve the SNR, ASL images are acquired at a
relatively low resolution (4 mm isotropic) and multiple control-label pairs are acquired to
permit signal averaging. Control-label pairs are acquired in interleaved succession to
minimize physiological sources of error such as cardiac pulsation and respiratory motion
[197].
ASL has relatively poor temporal resolution (4 - 8 s), since both a label and control
image are required to generate a perfusion weighted image. This can lead to increased
sensitivity to physiological and gross head motion. Since motion is more likely in older
and clinical populations [198], in addition to using foam in the head coil to limit motion,
post-processing steps including motion correction and sort-check algorithms [199] to
remove poor-quality volumes are implemented to minimize its effect. Emerging new
technical developments including labeling schemes, 3D imaging readouts, and background
suppression have contributed to the improvement in SNR [200].
Model parameters including the labeling efficiency and T1a can contribute to error
in CBF quantification. Continuous labeling is achieved by applying RF pulses to
manipulate the phase of flowing spins. The efficiency of the labeling process is affected by
field inhomogeneities and the flow velocity [189]. Typically, a the literature value (i.e.
85% for pCASL) obtained from simulations is adopted [189]. However, it can also be
estimated using PC [178] or a Look-Locker sequence [201]. Labeling efficiency can be
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maximized using an MR angiogram to position the labeling plane where the vessels are
fairly straight and orthogonal to the direction of flow [101].

The T1a depends on

hematocrit, blood oxygenation level and temperature [202]. Although subject specific
values can be measured using an inversion-recovery steady-state free precession MR
imaging sequence, typically a literature value is used (i.e. 1650 ms) [202]. Since errors in
the both the labeling efficiency and T1a calculation are reflected as a systemic shift in
global CBF, for studies assessing changes in CBF, all images will be affected in the same
manner and therefore will not affect the end result [203].
The most prominent source of error in CBF is variability in the ATT. Transit time
errors particularly affect clinical and older populations since with age and the presence of
disease, vessels in the brain become tortuous, resulting in delayed blood delivery [191].
Failure to account for the increased ATT could lead to misinterpretations of altered
perfusion related to normal aging with pathological alterations. To reduce the sensitivity
of the ASL signal to the ATT, a delay between the end of the labeling period and the start
of image acquisition (i.e. the PLD) was implemented to allow all of the labeled water to
reach the imaging volume [204]. The challenge with this approach is selecting the optimal
PLD. If the PLD is too short, the labeled blood has not fully reached the imaging plane,
whereas long PLDs lead to substantial reduction in the SNR due to T1 decay. Although the
PLD can be set based on recommendations from the literature [101], the ATT varies with
age, gender, pathology, and across the vascular territories [191,205]. For this reason, in
clinical populations, it is useful to verify that the ASL signal is insensitive to the ATT at
the selected PLD such that the ASL signal accurately reflects CBF. This can be achieved
by measuring the ATT using multi-PLD ASL sequences (Section 1.13.3, Chapter 3). A
recent study has proposed predicting the ATT based on the spatial coefficient of variation
of CBF [206]. A benefit to this approach is that ATTs can be predicted from single-delay
ASL scan, eliminating the necessity of an additional ATT mapping scan. However, further
validation studies are required to elucidate the accuracy of these predicted ATT values.
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1.14 Validation of ASL by 15O-water
Despite the promise that ASL shows with regards to its ability to quantify CBF and
its suitability for longitudinal studies, considering that the technique is completely noninvasive, the previously mentioned confounds demonstrate the need for further validation
of applications to specific clinical populations. This section provides an overview of studies
comparing perfusion by ASL to the reference standard, 15O-water.
Previous studies comparing ASL and

15

O-water showed good correlation of grey-

matter perfusion (R = 0.47 - 0.91) [207–211]. Although the correlation ranged from good
to excellent, measures of grey-matter perfusion by pCASL were on average ~ 15% higher
than 15O-water [207–209]. Where the aforementioned studies showed higher perfusion by
ASL, one study found systemically lower perfusion by pCASL (-15 ml/100g/min) [210]
and another found no difference [211]. This divergence could be related to differences in
the acquisition parameters. To account for potential variability in the transit times the study
showing no difference in grey-matter perfusion used a multi-PLD acquisition spanning 200
– 2000 ms whereas studies showing increased perfusion by pCASL implemented a shorter
PLD (1000 - 1525). The shorter PLD used in these studies could have led to an
overestimation in grey-matter perfusion due to residual vascular signal.
Regional correlation ranged between 0.61 - 0.83 [140,209–211]. In a comparison of
resting perfusion by CASL and 15O-water, Ye et. al., demonstrated that while perfusion in
the cortical strips were not significantly different, white-matter perfusion by ASL was 30%
lower [184]. Using parametric analysis Heijtel et al. demonstrated that pCASL
overestimates perfusion in deep cortical tissues and underestimated perfusion in the
prefrontal area, basal nuclei, and near the sagittal sinus [207]. Similarly, Puig et al. found
multi-PLD pCASL yields higher perfusion in the cingulate and insula, and lower perfusion
in the orbitofrontal cortex, inferior temporal lobes, cerebellum, and the cranial base [211].
These regional differences highlight the some of the tissue properties intrinsic to ASL.
White-matter perfusion imaging by ASL is known to have poor reliability and SNR due to
the low blood flow and the extended transit times [212]. Underestimations can be attributed
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to susceptibility artifacts at brain-air interfaces whereas overestimations in perfusion have
been linked to residual macrovascular signals in highly vascular regions [101].
Previous studies assessing longitudinal reproducibility of pCASL and

15

O-water in

healthy participants show comparable reproducibility across physiological states. Heijtel
et al. assessed within- and between-session (month-separated) reproducibility of ASL and
15

O-water at normocapnia and hypercapnia (between-session only) in 16 young healthy

participants [207]. At normocapnia, both within and between-session variability of ASL
(CV within = 9.3%, CV between = 12.8%) were comparable to

15

O-water (CV within =

12.0%, CV between = 14.1%). Furthermore, both techniques showed no difference in
within- and between session variability. Henriksen et al. also reported within-session
variability within a similar range for PASL (CV = 6.1%) and
[213]. At hypercapnia, between-session variability of

15

15

O-water (CV = 11.8%)

O-water (CV = 21.9%) was

considerably higher than pCASL (CV = 12.7%) [207]. Puig et al. assessed perfusion over
a range values (i.e. during hyperventilation, baseline, and post-acetazolamide) and
demonstrated strong correlation between ASL and 15O-water PET (R = 0.91) [211].
Most of the 15O-water/ASL comparison studies have focused on healthy participants.
Fewer studies have assessed the sensitivity of ASL relative to PET in clinical populations.
In an longitudinal study involving 14 participants at risk for or diagnosed with AD, Kilroy
et al. reported that pCASL had good regional correlation with PET (R = 0.51) and good
reproducibility and reliability within ROIs (CV = 10.9%, intraclass correlation coefficient
(ICC) = 0.707), highlighting the potential of pCASL for longitudinal imaging [140]. Xu et
al. assessed precision and reliability in 14 elderly participants (controls = 11, mild cognitive
impairment (MCI) = 2, AD = 1) and 8 young healthy participants. Their results showed
comparable reliability in elderly (ICC = 0.93) and young participants (ICC = 0.93) as well
as strong correlation between pCASL and

15

O-water in elderly participants (R = 0.74)

[214]. Neither of these studies assessed patient and control specific differences due to the
limited sample size. To avoid arterial sampling, both studies compared CBF by pCASL to
15

O-water in relative in units. Xu et al. normalized to the grand mean of whole brain blood

33

flow whereas Kilroy et al. scaled all images to a global mean of 50ml/100g/min. Given that
intensity normalization can introduce bias and limit the sensitivity for detecting
longitudinal perfusion changes [215], it would be valuable to investigate the agreement of
absolute perfusion. This topic is explored further in Chapter 4.
While these previous studies demonstrate the promise of ASL for longitudinal
imaging, there are some shortcomings that need to be addressed. First, many of the previous
studies were conducted on separate scanners which could introduce variability due to
physiological fluctuations between scans. The recent introduction of the PET/MR scanner
has allowed for simultaneous acquisition of data, eliminating this source of variance.
Second, beyond studies in dementia (i.e. AD) [140,214], cardiovascular disease [216–218],
diabetes [208], there are few studies that validate ASL against

15

O-water in clinical

populations. Given that sources of variability (e.g. physiological, ATT) reduce the
sensitivity for detecting perfusion change and introduce ambiguity into the interpretation,
further optimization and characterization of the minimum detectable perfusion change
could enable better delineation of physiological driven perfusion changes and noise. Most
notably, in FTD which shows heterogeneous patterns of hypoperfusion that are subtle in
the early stages.

1.15 Overview of Project
This thesis is focused on the validation ASL for characterizing longitudinal perfusion
changes in FTD and assessing its sensitivity for detecting disease-driven decreases in
perfusion.
Chapter 2 describes and validates a non-invasive MR reference-based approach for
quantifying

15

O-water CBF. Using a large-animal model, CBF over a range of

physiological conditions (hypocapnia, normocapnia, hypercapnia) was measured by the
established, but invasive, PET method and compared to CBF maps generated using the
non-invasive PET/MRI approach. This work was published in the Journal of Nuclear
Medicine.
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Chapter 3 evaluates the sensitivity of ASL relative to the reference standard

15

O-

water PET to detect regional perfusion abnormalities in individuals with frontotemporal
dementia. Optimized sequence parameters based on the ASL consensus paper were used
and to avoid arterial sampling, the non-invasive PET/MRI technique developed in Chapter
2 (PMRFlow) was implemented. This work was submitted for publication to Neuroimage:
Clinical.
Chapter 4 assesses the longitudinal reproducibility and reliability of ASL CBF as
well as the minimum detectable perfusion change. Using optimized ASL parameters, the
variability of perfusion data acquired ~30 minutes apart and from imaging sessions
separated by 3-4 weeks. These measures were quantified in healthy controls and
individuals with FTD. This work was published in Neuroimage: Clinical.
Chapter 5 summarizes the findings presented in this thesis, explores clinical
relevance, and areas for further exploration.
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Chapter 2

2

A Non-invasive Method for Quantifying Cerebral Blood
Flow by Hybrid PET/MR

2.1 Introduction
Given the critical role that proper regulation of cerebral blood flow (CBF) plays in
maintaining good brain health and function, there continues to be a search for perfusion
imaging techniques that are both quantitative and minimally invasive. The gold standard
for measuring CBF in humans remains positron emission tomography (PET) using
radiolabeled water (15O-water) [1]. However, quantification requires measuring the arterial
input function (AIF), which is not only an invasive procedure with a potential risk of
complications, but also sensitive to noise [2,3]. The magnetic resonance imaging (MRI)
technique, arterial spin labeling (ASL), is an attractive alternative as it is non-invasive and
in many respects the MRI analog of PET since it uses labeled water as a flow tracer [4]. A
number of validation studies have shown reasonable agreement between CBF
measurements from PET and ASL [5–8]; however, despite more efficient labeling
approaches and improvements in MR technologies, the precision of ASL can still be
limited by low signal to noise, and its accuracy hampered by arterial transit time effects
[9,10]. These issues become increasingly important when imaging low CBF, such as in
white-matter, older populations and patients with cerebrovascular disease [11–13].
Considering these current limitations of ASL, a PET-based approach that does not
require invasive arterial sampling but, could still generate quantitative CBF images would
be useful to measure CBF in challenging populations. One approach for circumventing
arterial catheterization is to extract an image-derived input function from dynamic PET
images [14]. The accuracy of this approach depends on careful correction for partial
volume effects, which is particularly challenging when deriving an image-derived input
function from carotid arteries given their relatively small size and the limited resolution of
PET scanners [15–17]. More recently, there has been a focus on minimizing partial volume
effects by co-registering anatomical MR images with PET images to aid with segmenting
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the feeding arteries [18]. The development of hybrid PET/MRI is attractive for this
approach as potential registration errors are reduced by simultaneous imaging [19].
An alternative PET/MR method for eliminating the need to measure the AIF would
be to adapt a reference-tissue approach. That is, CBF in a given voxel or region of interest
can be determined by relating its time activity data to that of a reference region with known
blood flow. The concept of using a reference-based method for PET 15O-water imaging has
been previously proposed [20], but this method required assuming a known value of global
CBF. With PET/MRI, this assumption is not necessary, given that CBF, either global or in
a chosen reference region, can be simultaneously measured by an MRI-based perfusion
method. This study presents a variation of this hybrid approach that uses an estimate of
whole-brain CBF measured by phase-contrast (PC) MRI [21] as a reference region. The
purpose of this study was to evaluate the accuracy of this hybrid imaging method using an
animal model in which global CBF was varied by manipulating arterial CO2 tension
(PaCO2). For validation CBF was also determined independently from the PET data by
directly measuring the AIF.

2.2 Materials and Methods
2.2.1

Validation Study

Animal experiments were conducted according to the guidelines of the Canadian
Council on Animal Care, and approved by the Animal Use Committee at Western
University. Eight female juvenile Duroc pigs were obtained from a local supplier (age: 810 weeks, weight: 19.6 ± 3.0 kg). Under 3% isoflurane anesthesia, animals were
tracheotomized and mechanically ventilated on a mixture of oxygen and medical air.
Catheters were inserted into the cephalic veins for

15

O-water injections and the femoral

arteries for intermittent blood sampling, measure PaCO2 and arterial O2 tension, monitor
blood pressure and measure the AIF. Following preparation and surgical procedures,
animals were transported to the PET/MR imaging suite on a custom immobilization
platform and allowed to stabilize for approximately 1 hour before the experiment started.
While in the scanner, animals were anesthetized with a combination of isoflurane (1 - 3%)
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and an intravenous infusion of propofol (6 – 25 mL/kg/hour). A pulse oximeter was used
to monitor arterial oxygen saturation and heart rate. At the end of the experiment, animals
were euthanized according to the animal care guidelines.

2.2.2

Study Protocol

The study consisted of simultaneously collecting 15O-water PET and PC-MRI data.
CBF was changed by adjusting the ventilator’s breathing rate and tidal volume to vary
PaCO2 from hypo- to hypercapnia. For each animal, CBF measurements were obtained
under two of three possible PaCO2 levels (hyper-, normo-, and hypercapnia), which were
randomly selected per experiment. The number of conditions was limited to two per animal
due to considerations regarding the duration of each experiment and blood loss, which was
primarily related to measuring the AIF. Before and immediately after each CBF
measurement, arterial blood samples were collected to record PaCO2. Experiments were
conducted on a 3T Siemens Biograph mMR PET/MR system using a 12-channel PETcompatible head coil (Siemens GmbH, Erlangen, Germany). 15O-water was produced by
an onsite cyclotron (GE PETTrace 800, 16.5 MeV) by the (d,n) N-14 reaction. Prior to
CBF data acquisition, sagittal T1-weighted images, which were subsequently used for
anatomical reference and to create whole brain masks, were acquired using a 3D
magnetization-prepared rapid gradient-echo sequence (TR (repetition time)/TE (echo
time): 1780/2.45 ms, inversion time: 900 ms, flip angle: 9°, field of view: 180 x 180 mm2,
176 slices, isotropic voxel size: 0.7 mm3). Followed by the acquisition of 3D time-of-flight
magnetic resonance angiography (TOF-MRA) (TR/TE: 22/3.6ms, matrix: 320 x 320 x 105,
voxel size: 0.8 x 0.8 x 1.5 mm3) (Figure 2.1). Finally, to align the Computed Tomography
(CT) data used for attenuation correction, to the PET data, ultra-short echo time contrast
images were acquired (TR/TE1/TE2: 11.94/0.07/2.46 ms, field of view: 300 x 300 mm2,
192 slices, isotropic voxel size: 1.6 mm3).
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Figure 2.1: CBF measurement by PC. Sagittal T1-weighted image for
anatomical reference. The red area represents the imaging region for the
TOF-MRA (B) which was used for planning for PC acquisition.
Exemplary magnitude (C) and phase (D) images. ROIs (red) on the
basilar artery (BA) and internal carotid arteries (ICA) were contoured
on the magnitude image and copied to the phase image.

A flow experiment was performed once PaCO2 was considered stable, as confirmed
by two readings within 2 mmHg of each other. The experiment began by a manual
intravenous bolus injection of 15O-water (423 ± 130 MBq, 8 ml), followed a saline flush
(10 ml), and simultaneous acquisition of dynamic

15

O-water PET and PC-MRI data.

Following data acquisition, PaCO2 was altered to achieve a different CBF level and the
procedure was repeated after a delay of at least 20 min to allow sufficient decay of

15

O

activity and to ensure PaCO2 had stabilized to its new level. At the end of the two
conditions, the pig was transported on an immobilization platform to either the Revolution
CT scanner or Discovery VCT PET/CT (GE Healthcare, Waukesha, WI) to obtain a CTbased attenuation correction map (protocols were identical) (slice thickness: 1.25 mm,
Energy: 140 kV, field of view: 1024).
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2.2.3

Phase Contrast MRI Acquisition and Post-Processing

At each PaCO2, gated PC images were acquired (TR/TE: 34.4/2.87 ms, matrix: 320
x 320, voxel size: 0.625 x 0.625 x 5 mm3, velocity encoding: 80 cm/s in the through-plane
direction [22,23], 8 averages, 8 segments, duration: 7 minutes) simultaneous to 15O-water
PET acquisition [24].
PC data were converted into global CBF [22,25] using an in-house written
MATLAB (MathWorks, Natick, MA) script. Contours of the basilar and internal carotid
arteries for each segment of the cardiac cycle were manually delineated on the magnitude
image and copied to the phase image (Figure 2.1). Vessels were contoured 3 times to obtain
an average measurement which was then used to calculate global CBF.

2.2.4

15

O-Water PET Acquisition and Post-processing

Following the 15O-water injection, five minutes of list-mode data were acquired [26].
A MR-compatible automated blood sampling system was connected to a catheter in a
femoral artery to measure the AIF (Swisstrace GmbH, Menzingen, Switzerland). The
sampling system was attached to a pump set to a withdrawal rate of 5 mL/min and recorded
activity at a temporal resolution of 1s. The system was started approximately 15s before
injecting 15O-water and continuously recorded 15O-water activity throughout the scan. The
tubing connecting the arterial catheter to the detector was 15cm long. A calibration
experiment was performed prior to the study, which showed that the effect of dispersion
was negligible at the withdrawal rate and tubing length used in this study.
Reconstruction of the PET images was performed offline using Siemens e7-tools
suite for Biograph mMR data. Raw PET data were corrected for scatter, random incidences,
detector normalization and data rebinning. Attenuation correction was performed using
CT-based attenuation correction maps that were rescaled to the annihilation emission
energy (511 keV) [27] and aligned to the ultra-short echo time images. PET data were
reconstructed into 37 dynamic frames (3 s x 20; 5 s x 6; 15 s x 6; 30 s x 5) using a 3D
ordered subset expectation maximization algorithm with 4 iterations and 21 subsets [28].
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Reconstructed PET images (matrix size: 344 x 344 x 127, voxel size: .8 x .8 x 2 mm, zoom
factor: 2.5) were smoothed by a 6-mm Gaussian filter.
Dynamic PET images were analyzed two ways using in-house developed MATLAB
to generate separate sets of CBF images. First, by the standard PET-only method using the
measured AIF:
𝑡

𝐶𝑖 (𝑡) = 𝑓𝑖 ∫ 𝐶𝑎 (𝑢)𝑒 −𝑘2(𝑡−𝑢) 𝑑𝑢 + 𝐶𝐵𝑉𝑎 ∙ 𝐶𝑎 (𝑡)

(2.1)

0

where 𝑘2 is the clearance rate constant, Ca(t) is the AIF, and CBVa is the arterial
blood volume. The delay between the AIF and the PET tissue activity data was corrected
by aligning the initial rise (approximately the first 10 seconds) of the AIF to an imagederived input function derived from the carotid arteries of the corresponding dynamic PET
data. Spill-in and spill-out corrections were not performed since only the initial appearance
of 15O-water was of interest. With the two data sets aligned, the MATLAB routine for nonlinear optimization (fmincon) was used to fit Eqn. (2.1) to tissue activity curve to generate
best-fit estimates of CBF, k2 and CBV. This analysis was conducted using the whole-brain
time activity curve for comparison to whole-brain CBF (fwb) from PC-MRI and at the
voxel-by-voxel level to generate CBF images.
The MR-reference region approach for generating CBF images is given by Eqn.
(2.2)[20,29]:
𝑇

𝑓𝑖 =

∫0 𝐶𝑖 (𝑡) 𝑑𝑡
1 𝑇
1 𝑇 𝑡
1 𝑇 𝑡
𝐶𝑤𝑏 (𝑡) 𝑑𝑡 + ∫0 ∫0 𝐶𝑤𝑏 (𝑠) 𝑑𝑠 𝑑𝑡 − ∫0 ∫0 𝐶𝑖 (𝑠) 𝑑𝑠 𝑑𝑡
∫
0
𝑓𝑤𝑏
𝜆
𝜆

where Ci(t) and fi are the tissue
voxel/region, Cwb(t) is whole-brain tissue

15

(2.2)

O-water concentration and CBF in the ith

15

O-water concentration, and λ is the partition

coefficient of water. An important distinction between the PET-only and MR-reference

60

methods is the latter is based on the assumption that arterial blood-borne activity has
negligible effects on the calculation of CBF in the ith voxel/region (fi).

2.2.5

Statistics

Agreement between whole-brain CBF measurements from

15

O-water and PC was

assessed by linear regression analysis and Bland-Altman plots. Linear regression was also
used to assess the spatial agreement between CBF images created by the two methods. To
minimize the effects of spatial correlation, the analysis was conducted using large ROIs
that encompassed cortical tissue, deep grey-matter, and cerebellum. These ROIs were
created based on T1-weighted images and averaged over adjacent slices to minimize spatial
correlation in the axial direction as well. To assess whether the slope and intercept were
significantly different from 1 and 0 respectively, t-tests were conducted. p-values less than
.05 were considered significant. For all measurements the mean plus/minus the standard
deviation are reported.

2.3 Results
2.3.1

Validation Study - Porcine Model

Data were acquired in juvenile pigs at hypocapnia (n = 5, PaCO2 = 29.0  3.6),
normocapnia (n = 5, PaCO2 = 39.7  2.2), and hypercapnia (n =4, PaCO2 = 54.3  7.3).
Each animal was scanned at two arterial CO2 tensions ranging between 23 and 63 mmHg.
For two animals, data from one PaCO2 condition was excluded due to failure of the blood
sampling system and another due to unexpected death.
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2.3.2

Whole Brain Cerebral Blood Flow

Global CBF measured by the PET-only method and PC-MRI at hypo-, normo- and
hypercapnia are reported in Table 2.1. Figure 2.2A shows a scatter plot correlating wholebrain CBF measured by the two imaging modalities. The correlation coefficient (R2 = 0.9)
and linear regression (slope: 0.88, intercept: 7.1) demonstrated strong and significant
correlation between the variables (p < 0.001). Furthermore, the intercept and slope were
not significantly different from zero and one, respectively (p > 0.05). Bland-Altman
analysis demonstrated little systematic bias, indicated by a mean difference of 0.16
ml/100g/min (Figure 2.2B).

Table 2.1: Summary of global CBF measured by the PET-only and MRreference approach and regional CBF regression parameters (slope,
intercept, R2) at each PaCO2. Asterisks indicate intercepts significantly
different from zero (p < 0.05). Slopes were not significantly different from
one (p > 0.05).
Condition

MR reference CBF PET only CBF

Slope

Intercept
(mL/100g/min)

R2

(mL/100g/min)

(mL/100g/min)

Hypocapnia

36.5 ± 6.6

34.3 ± 6.0

Normocapnia

54.3 ± 6.6

57.5 ± 10.0 1.14 ± 0.28

Hypercapnia

92.3 ± 8.4

87.4 ± 10.6 1.28 ± 0.22 -43.5 ± 20.4* 0.96 ± 0.02

1.14 ± 0.18 -4.9 ± 2.4* 0.98 ± 0.01
-9.3 ± 8.7

0.97 ± 0.02
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Figure 2.2: Whole-brain CBF comparison: (A) Correlation between CBF
measured by

15O-water

and PC (n = 14). The solid line represents the

regression line (equation: y = .88 x - 7.1 ml/100g/min) and the line of
identity is dashed. (B) Bland-Altman plot comparing the difference (xaxis) and average (y-axis) of 15O-water and PC CBF (n = 14). The mean
difference and limits of agreement are indicated by the dashed lines.
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2.3.3

Regional Cerebral Blood Flow

Representative CBF images generated by the PET-only technique (Eqn. (2.1)) and
the MR-reference method (Eqn. (2.2)) at each PaCO2 level are shown in Figure 2.3.

Figure 2.3: CBF measured by PET-only and the MR-reference
approaches from a representative set of animals at three PaCO2 ranges.
T1-weighted images are shown on the left for anatomical reference.

Similar perfusion patterns can be observed with both methods, with higher blood
flow evident in cortical grey-matter, thalamus, and the cerebellum. At hypercapnia, the
MR-reference technique tended to yield higher estimates of CBF in the midbrain regions.
Linear regression plots of the ROI-based CBF values from the two techniques were
generated to assess spatial agreement. Average regression parameters are summarized in
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Table 1. Example regional correlation plots at the 3 arterial CO2 tensions are shown in
Figure 2.4.

Figure 2.4: Regional CBF scatter plots in deep grey-matter (white),
cerebellum (black), cortical grey-matter (grey) at: (A) hypocapnia, (B)
normocapnia and (C) hypercapnia. Each scatter plot is generated using
data from one representative animal. The equation represents the bestfit of a linear regression model.
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2.4 Discussion
The goal of this work was to develop a non-invasive

15

O-water-PET method of

measuring CBF using hybrid imaging to avoid directly measuring the AIF. Simultaneous
PET/MRI provides the ability to use a reference-based method since global CBF can be
measured by PC-MRI or alternatively CBF in a specific brain region could be measured by
ASL. For this study, we chose the former since PC-MRI is a fast and relatively simple
technique to implement[30,31]. In fact, it is often used in ASL studies as a means of
measuring labeling efficiency[25]. Rather than simply normalizing PET activity images
by an MRI measurement of global CBF, a modelling approach initially proposed by Meija
et al.[20] was implemented to account for the nonlinearity between PET activity and CBF.
The accuracy of the method was tested in a porcine model since they have a relatively large
brain with good grey-to-white matter contrast, and similar CBF values to humans[32]. As
well, the use of an animal model enabled the technique to be evaluated over a wide range
of flows (25 to 110 ml/100g/min) that would be difficult to achieve with human
participants. Average whole-brain CBF values measured at normocapnia (57.5 ± 10.0, and
54.3 ± 16.6 ml/100g/min by PET and PC-MRI, respectively) were in line with previous
studies reporting values between 45 and 62 ml/100g/min[32–34]. In addition, strong
correlations between CBF values measured by PC-MRI and 15O-water-PET both globally
and regionally were found.
Although PC-MRI is an established technique for measuring global CBF[30,31], it
has some technical limitations. Suboptimal imaging plane selection and coarse image
resolution can result in partial volume errors if voxels contain both moving fluid and
stationary vessel wall tissue[21,24,35,36]. Additionally, the chosen velocity encoding can
potentially introduce error: too small of a value will lead to aliasing, while too large of a
value will result in poor signal-to-noise ratio[22]. To avoid these errors, the imaging plane
was carefully selected based on a maximum intensity projection of the TOF-MRA, and the
voxel size was chosen such that at least 9 voxels covered the lumen of the larger vessels.
Lastly, velocity encoding was set to 80 cm/s[23] in order to measure both low and high
flows at hypo- and hypercapnia, respectively. A recent study comparing CBF

66

measurements from PC-MRI and 15O-water-PET in healthy human subjects reported only
a moderate correlation between the two techniques and significantly higher values from
PC-MRI – up to 63% overestimation[37]. This is in contrast to the current study, in which
a strong correlation was found (Figure 2.2A: slope = 0.88, intercept = 1.7 ml/100g/min, R2
= 0.9) with an insignificant systematic bias of 0.16 ± 7.6 mL/100g/min (Figure 2.2B). It is
difficult to know the specific reason for this difference. A contributing factor may be
variability in CBF between MRI and PET measurements, which was avoided in the current
study by simultaneous acquisition. The systematic offset observed in the previous study
may have been caused by phase errors in the non-gated PC sequence due to flow pulsatility
in the feeding arteries[31]. Regardless of the reason, the discrepancy between the studies
highlights the importance of ensuring the accuracy of the MRI method used for calibration.
Having established no significant difference in global CBF measured by PC-MRI
and 15O-water-PET, spatial agreement of CBF maps generated by the standard PET-only
approach and the proposed MR-reference method was conducted. Linear regression
analysis of the regional CBF maps showed excellent correlations at all capnic conditions
(R2 = 0.96 – 0.98). Good agreement was found at hypo- and normocapnia, as indicated by
the near unity regression slopes and small intercept values (Table 1), and shown in the
representative CBF maps (Figure 2.3). However, indicated by the increased slope at
hypercapnia, there was less agreement in CBF values measured by the two methods;
particularly in deep grey-matter (Figure 2.3 and Figure 2.4C). Note that the increased
magnitude of the intercept at hypercapnia reflects bias due to the primarily high flow rates.
The discrepancy at hypercapnia may have been caused by neglecting blood-borne
activity since its relative contribution will increase with elevated CBF due to vessel
dilation. Simulations (S Figure 2.1) predicted that this error should be fairly small for an
integration time of 5 min. This is expected considering that unlike the PET-only method,
which is sensitive to the arterial blood activity in a given voxel, the reference-based method
is only sensitive to the difference in blood volume between a voxel and the reference
region. However, the error in a highly vascularized voxel could be greater if the ratio of
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CBV to CBF was greater than the model prediction, which was based on Ito et al.[38]. An
alternative explanation could be cross talk between fitting parameters for the PET-only
approach (i.e. fi and CBVa), which could lead to an underestimation of CBF at high values.
While the results of this study demonstrated good agreement between CBF values
from the MR-reference and the gold standard PET-only approach over a flow range from
about 30 to 100 ml/100g/min, there are some potential limitations. First, internal dispersion
was not included in the PET-only analysis since an appropriate value of a dispersion time
constant was unknown, but likely less than a value of 5 s commonly used in human studies
given the smaller size of these animals (weight ~ 20 kg). A second consideration is the
approach used to position the PC slice, which was based on manual planning using TOF
images. Recent studies have implemented automatic planning schemes that enable an
optimized selection of the imaging plane[35].

2.5 Conclusion
In summary, we believe this non-invasive hybrid PET/MRI approach could be useful
for imaging CBF in patient populations for whom it has proven challenging to obtain
accurate measurements by other methods, most notably ASL, due to transit time delays
resulting from significant vascular disease. Eliminating arterial sampling not only makes
the MR-reference approach minimally invasive, it also avoids noise contributions from the
AIF and associated errors due to dispersion and delay[39].
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Supplemental Figures

S Figure 2.1: (A) Predicted error in CBF caused by not accounting for
blood-borne activity. Tissue activity curves including vascular tissue
activity (Eqn. 1) were generated for regional/ith voxel CBF (fi) from 10100 mL/100 g/min using a theoretical arterial input function. Arterial
blood volume in a voxel (CBVi) was estimated based on: CBVi = CBVwb
*(fi/fwb)0.29, where fwb is whole brain CBF and CBVwb is whole brain
arterial blood volume. To predict error in CBF from using the MRreference approach (Eqn. 2), fi was calculated with fwb = 50 mL/100 g/min
and λ = 90mL/100g. The percent error in the MR-reference CBF (relative
to the corresponding input values) was plotted against the input CBF
values for acquisitions lengths of 1 - 5 minutes. Error in CBF was less
than 2% over the entire range of CBF values for acquisition lengths
greater than 3 minutes. (B) Simulated tissue activity curves with (blue)
and without (red) an arterial contribution.
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Chapter 3

3

Concordance of Regional Hypoperfusion by pCASL
MRI and 15O-water PET in Frontotemporal Dementia: Is
pCASL an Efficacious Alternative?

3.1 Introduction
Frontotemporal dementia (FTD) is a heterogeneous class of syndromes characterized
by progressive degeneration of the frontal and temporal lobes. Clinically, FTD is
subdivided into behavioural variant (bvFTD), which presents with changes in personality;
primary progressive aphasias including the semantic variant (svFTD) and nonfluent
agrammatic variant PPA (nfPPA), which present with language impairment; and the related
syndromes including, corticobasal syndrome (CBS) and progressive supranuclear palsy
(PSP), presenting as affected motor control and coordination [1]. While early diagnosis is
critical for timely inclusion in clinical trials, accurate differential diagnosis at the early
stages remains a challenge due to the overlap of clinical symptoms not only among
subtypes but also with neuropsychiatric diseases including Alzheimer’s disease and
schizophrenia [2,3].
Functional brain imaging methods are commonly used to provide objective measures
of disease progression that are more sensitive than changes in brain volume [4]. Glucose
metabolism by

18

F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a

well-established measure that is highly correlated with neuropsychiatric scores [5] and used
clinically for improving diagnostic confidence [6,7]. Due to the tight relationship between
metabolism, blood flow, and brain activity, perfusion can also be used as a marker of brain
health. The current standard for imaging perfusion is PET with radiolabeled water (15Owater) as it provides quantitative and stable results with a short scan period (2-5 minutes)
[8]. Despite the demonstrated value of these PET-based techniques, PET imaging is
expensive and access limited. Furthermore, perfusion imaging using

15

O-water is

challenging due to the short half-life of the tracer and quantification requires arterial
sampling, which is invasive and sensitive to noise.
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Arterial spin labeling (ASL) is an attractive alternative since it is totally non-invasive
and quantitative. As an MRI-based technique, it is more accessible, cost-effective, and less
technically demanding than PET. Furthermore, with the emergence of tracers for
investigating

dementia

pathophysiology,

including

tau

accumulation

and

neuroinflammation, implementing ASL as a marker of metabolic/perfusion deficits “frees”
PET for more targeted studies [9]. Several studies have investigated the ability of ASL to
differentiate between FTD and Alzheimer’s Disease (AD) [10–14]; however, there has
been a dearth of studies assessing perfusion changes among the FTD subtypes. Expected
patterns of regional hypoperfusion have only been identified in a few subtypes, namely
bvFTD [10,15], and svFTD [4]. Beyond group analysis involving patients with nfPPA [13]
and FTD-related disorders including PSP and CBS [16], to date there have been no studies
assessing regional hypoperfusion associated with these subtypes.
Considering that prognosis and treatment options differ between subtypes [17], the
aim of this study was to assess the ability of ASL to detect regional perfusion deficits
related to FTD and related disorders. Hypoperfusion was determined using single-delay
pseudo continuous ASL (SD-pCASL), as it is the recommended version for dementia
studies [18], as well as free lunch Hadamard time encoded pCASL (FL_TE-pCASL),
which is able to quantify transit-time corrected perfusion in a time-efficient manner [19].
In contrast to previous studies that compared perfusion to glucose metabolism [15,20–22],
the current study is the first to perform a head-to-head comparison to 15O-water PET. Given
that up to 61% of FTD cases have a vascular component, [23,24], potential differences
related to perfusion-metabolism decoupling are avoided. Furthermore, by taking advantage
of hybrid PET/MRI, cerebral perfusion could be imaged simultaneously by pCASL and
15

O-water, thereby avoiding potential differences related to repositioning and physiological

fluctuations. This study focused on single-subject analysis to account for the heterogeneity
of perfusion deficits between FTD subtypes and to reflect the use of imaging in clinical
studies.
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3.2 Materials and Methods
3.2.1

Study Participants

Eleven patients with FTD or PSP and 13 age-matched neurologically healthy controls
were enrolled between November 2019 and July 2021. Patients were recruited from the
Cognitive Neurology and Aging Brain clinics at Parkwood Hospital (St Joseph’s Health
Care London), while controls were recruited through the clinic’s volunteer pool. Diagnosis,
performed by a clinical neurologist (E.F.), followed established consensus criteria for
probable FTD [25,26] or PSP [27] and included neuropsychological testing, clinical MRI,
and genetic testing. Participants completed standardized psychometric assessments (Table
3.1) to evaluate domains of cognition. Patients’ study partners completed ratings of
symptoms and behaviours. Exclusion criteria included any significant neurologic or
psychiatric disorders other than suspected FTD, any significant systemic illness, and MRI
incompatibility.

Table 3.1: Summary of demographics and scores from standardized
psychometric assessments.
Patients

Controls

Demographics
Sex (M:F)
Age (years)

Diagnosis

3:6

8:5

68.9 ± 8.2

64.1 ± 9.9

2 bvFTD
2 nfPPA
3 svFTD
2 PSP

-
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Cognitive Measures
N

Score

N

Score

ACE-III Total Score
(American Version A)

9

60 ± 16.6

13

92.2 ± 3.7§

Mini-ACE Total Score (30)

9

15 ± 6.9

13

27.7 ± 2.5§

Attention (18)

9

15 ± 2.2

13

16.7 ± 2

Memory (26)

9

12.6 ± 7.6

13

23.5 ± 2.8§

Fluency (14)

9

4.3 ± 3.2

13

11.8 ± 2.2§

Language (26)

9

15.8 ± 7.8

13

25.4 ± 1.1§

Visuospatial (16)

9

12.3 ± 2.2

13

14.8 ± 1.1§

Boston Naming (15)

9

5.9 ± 5.9

10

13.7 ± 1.6§

Geriatric Depression Scale
(Short Form; 15)

9

5.1 ± 2.7

10

1.9 ± 3.7§

Neuropsychiatric Inventory
Total Score (144)

8

14.3 ± 14.7

-

-

FBI Total Score (72)

9

24.3 ± 12.9

-

-

Cornell (38)

8

8.5 ± 5.4

-

-

Cambridge Behavioural
Inventory Revised (180)

9

49.6 ± 19.7

-

-

Caregiver Measures

Values are expressed as the mean ± standard deviation.
Values in parenthesis represent the maximum score for each test.
T-tests were conducted to test for differences in cognitive measures between patients and controls.
Statistical significance (p < 0.05) is indicated by §

The study was approved by the Western University Health Sciences Research Ethics
Board and was conducted in accordance with the Declaration of Helsinki ethical standards.
Participants provided written informed consent in compliance with the Tri-Council Policy
Statement of Ethical Conduct for Research Involving Humans.

77

3.2.2

PET/MRI Acquisition

PET and MRI data were acquired on a hybrid PET/MRI scanner (Siemens Biograph
mMR) using a 12-channel PET-compatible head coil. Five minutes of list mode data were
acquired immediately after a bolus injection of 15O-water through the antecubital vein (741
± 67 MBq). PET data were reconstructed to 37 image volumes (frames: 3sx20,
5sx6,10sx6,30sx5, FOV: 172x172x127mm3, voxel-size: 2.09x2.09x2.03 mm3) using a
vendor-based MR attenuation correction map (Dixon plus bone [28,29]) and an iterative
algorithm (ordinary poisson ordered subset expectation maximization, 3 iterations, 21
subsets, 3D Gaussian filter of 4 mm) with corrections for decay, scatter, and dead time.
PMRFlow [30] was implemented to generate quantitative perfusion images by 15Owater without arterial blood sampling. Briefly, whole-brain perfusion measured by phase
contrast (PC) MRI was used to calibrate 15O-water images. The internal carotid (ICA) and
vertebral arteries (VA) were identified using a 3D time-of-flight MRI angiography and the
PC imaging plane was angulated perpendicularly to these vessels with a focus on
optimizing the angle for the larger vessels (i.e. ICAs). Retrospectively gated PC images
were acquired simultaneously to the

15

O-water acquisition (TR/TE: 43.8/4.39ms, voxel

size: 0.7 x 0.7 x 5mm3, FOV: 263x350x350 mm3, velocity encoding: 70cm/s in the through
plane direction, segments: 3). Twelve phases per cardiac cycle with four averages were
acquired for a total scan time of ~4-5 minutes, depending on the participants heart rate.
Within 5 minutes of the PET scan, SD-pCASL data were acquired with a 4-shot gradient
and spin echo (3D-GRASE) readout [31]; TR/TE: 4500/22.14 ms, voxel-size: 4 mm
isotropic, FOV: 256 x 256 x 128 mm3, label-control pairs: 16, bandwidth: 2298Hz/Px, 1
preparing scan, scan time: 9:46 min. In accordance with guidelines for imaging clinical
populations, the post-labeling delay (PLD) and labeling duration (LD) were set to 2000
ms and 1800 ms, respectively [18]. To quantify perfusion in physiological units, an
equilibrium magnetization (M0) with identical parameters except for a TR of 7000 ms
and no background suppression or labeling was used.
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FL_TE-pCASL images were acquired with a 2-shot GRASE readout with TR/TE:
5500/21.22 ms, voxel-size: 5 mm isotropic, FOV: 320 x 215 x 120 mm3, bandwidth: 2894
Hz/Px, slice partial Fourier: 6/8, phase partial Fourier: 6/8, 4 measurements per PLD, scan
time: 5:52 minutes. With FL_TE-pCASL, the traditional PLD is replaced with timeencoding blocks [19,32]. An N = 8 Hadamard scheme was applied with sub-bolus duration
of 250 ms, free-lunch LD of 2000 ms, and PLD = 200 ms. This corresponded to PLD1/LD1:
1700 ms/2000 ms, and LD2-7: 250 ms, PLD2-7: 1450, 1200, 950, 700, 450, 200 ms. An M0
image was acquired with identical parameters except no background suppression or
labeling.
For each participant, the labeling plane offset of pCASL sequences were adjusted (90
- 125 mm from the center of the imaging slab) to ensure the vessels were parallel to the
labeling plane [33]. Background suppression was achieved using two inversion pulses to
null components with T1 of 700 and 1400 ms [31]. This was implemented in both pCASL
sequences.
T1-weighted images, used for anatomical reference and to generate brain masks,
were acquired using a 3-dimensional magnetization prepared rapid acquisition gradient
echo (MPRAGE) sequence (TR/TE: 2000/2.98 ms, voxel size: 1 mm isotropic, field of
view (FOV) 256 x 256 x 176 mm3, scan time: 4:38 minutes).

3.2.3

Image Processing

Image analysis was performed with the Oxford Centre for Functional MRI of the
Brain (FMRIB)'s software library (FSL 6.0.1)[34], SPM12 (http://www.fil.ion.ucl.ac.uk)
[35], and in-house MATLAB scripts (MATLAB 2018a, The MathWorks, Natick, MA).
All images were manually reoriented to the axis of the anterior and posterior commissure.
T1-weighted images were processed by the fsl_anat pipeline to generate bias-corrected,
skull-stripped, tissue-segmented, and spatially normalized structural images, as well as a
normalization matrix [36].
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3.2.4

15

O-water PET Perfusion Quantification

Generating quantitative CBF images with PMRFlow requires determining wholebrain CBF, fwb, by PC MRI. The procedure involved drawing contours of the ICA and VA
on the magnitude image that were copied to the phase image using in-house developed
MATLAB scripts. Contours were visually inspected for correctness. Average velocity was
calculated based on the linear relationship between phase change and velocity encoding
[37]. Whole-brain CBF was quantified by multiplying the average velocity within each
vessel by its cross-sectional area, scaling by brain tissue mass, and summing contributions
from all vessels.
Perfusion images were generated using the following equation [30]:
𝑇

𝑓𝑖 =

∫0 𝐶𝑖 (𝑡) 𝑑𝑡
1 𝑇
1 𝑇 𝑡
1 𝑇 𝑡
𝐶𝑤𝑏 (𝑡) 𝑑𝑡 + ∫0 ∫0 𝐶𝑤𝑏 (𝑠) 𝑑𝑠 𝑑𝑡 − ∫0 ∫0 𝐶𝑖 (𝑠) 𝑑𝑠 𝑑𝑡
∫
0
𝑓𝑤𝑏
𝜆
𝜆

(3.1)

where fi is CBF in the ith voxel, Ci(t) the corresponding tissue 15O-water time activity
curve (TAC), Cwb(t) the whole-brain TAC, λ the partition coefficient of water, and T the
integration time (5 min). Resulting perfusion maps were spatially normalized to the MNI
template using a non-linear image registration tool (FNIRT [38]) and smoothed by a 6 mm
gaussian filter. This resulted in an effective resolution of 8.8 - 9.4 mm for PET.

3.2.5

pCASL MRI Perfusion Quantification

All pCASL (SD-pCASL and FL_TE-pCASL) images were motion corrected and
registered to the M0 image using SPM12. The remaining processing steps were
implemented using FSL’s Oxford ASL toolbox. Motion-corrected images were pairwise
subtracted, and ENABLE[39] was implemented to remove poor quality image volumes.
Perfusion was quantified using a single compartment model including Bayesian inference
to perform kinetic modeling to spatially regularize the images [40]. Model parameters were
based on the guidelines of the ASL consensus paper [18]. Images were normalized to the
MNI template using FNIRT [38], smoothed by an 8 mm Gaussian filter (resulting in an
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effective resolution of 9.2 and 9.6 mm for SD-pCASL and FL_TE-pCASL respectively),
and intensity normalized to global perfusion measured by PC MRI (i.e., global perfusion
measured by 15O-water and pCASL were equivalent).

3.2.6

Statistics

Statistical analysis was performed using MATLAB and R (R Core Team 2013).

3.2.6.1

Hypoperfusion Maps by Case Control Analysis

Recognizing the heterogeneity between FTD subtypes, perfusion images from each
patient were compared individually to the groupwise perfusion images from the
controls[15]. Crawford and Howell’s modified t-test was used to account for the small
sample of the control group. Treating the control mean and standard deviation as sample
statistics, allowed for better characterization of the uncertainties in these values, thereby
minimizing Type I errors [41]. The critical t-value for a one-sided t-test was determined
based on the size of the control group for alpha 0.05. Hypoperfusion maps for each patient
were generated using absolute perfusion (aCBF) and relative perfusion (rCBF, intensity
normalized to whole brain CBF).

3.2.6.2

Agreement Between PET and MRI-based Hypoperfusion

Agreement in regional hypoperfusion detected by

15

O-water and pCASL was

characterized in terms of sensitivity and specificity. Twelve ROIs commonly associated
with FTD and PSP and one reference region were selected from wfupickatlas: the
amygdala, anterior cingulate cortex, inferior frontal gyrus, insula, midbrain, orbitofrontal
gyrus, precuneus, supplementary motor area, superior frontal gyrus, temporal pole, middle
temporal lobe, superior temporal lobe, and the occipital lobe (reference region). ROIs were
classified as hypoperfused if they contained greater than 65 connected and significantly
hypoperfused voxels. This threshold corresponds a sphere with 1 cm diameter, which was
considered the smallest volume that could be reasonably visually identified. This method
is similar to visual rating scales where regional atrophy is identified within disease specific
ROI[42]. Agreement was calculated using the ROIs detected by

15

O-water as the gold
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standard. It is important to distinguish that this is a measure of similarity between
hypoperfusion maps generated by 15O-water and pCASL rather than an assessment of the
clinical accuracy of regional hypoperfusion.
Voxel-by-voxel agreement between 15O-water and pCASL hypoperfusion maps was
characterized based on the number of voxels that were overlapping (voxels detected by
both pCASL and

15

O-water), adjacent (voxels detected by pCASL that are adjoining

overlapping voxels), and isolated (pCASL voxels not connected to clusters adjoining 15Owater regions). These parameters were expressed as a percent of the total number of
hypoperfused voxels detected by pCASL. The Jaccard similarity coefficient was calculated
to characterize the similarity between hypoperfusion detected by pCASL relative to

15

O-

water[43].
Paired t-tests, linear regression, and Bland-Altman plots were used to compare
regional perfusion measured by 15O-water and pCASL. Statistical significance was set at
p<0.05.

3.3 Results
3.3.1

Participants

Two patients were excluded due to issues with 15O-water production in one case and
an unforeseen illness in the other case. One svFTD patient received an oral dose of
lorazepam prior to the scan to manage anxiety associated with claustrophobia. This patient
was excluded from the aCBF analysis due to its known effects on global CBF. FL_TEpCASL data were acquired in nine control and all eight patients. Demographics and clinical
characteristics of the participants are summarized in Table 3.1.

3.3.2

Global Perfusion

Whole-brain CBF measured by PC MRI was 41 ± 8.6 and 48.1 ± 7.7 ml/100g/min in
patients and controls, respectively. All perfusion maps showed the expected contrast of
higher perfusion in grey-matter relative to white-matter (Figure 3.1). Compared to

15

O-
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water, the two pCASL sequences showed lower perfusion in the basal ganglia, and greymatter perfusion appeared more dispersed. Despite these differences, disease-related
regional hypoperfusion was apparent in the CBF images from all three methods. In the
example, low perfusion was observed in the left temporal lobe for the patient (svFTD2).

FL-pCASL

SD-pCASL

15O-water

svFTD 2

0
100
CBF (ml/100g/min)

Control
Average

0
80
CBF (ml/100g/min)

Figure 3.1: Perfusion maps generated by FL_TE-pCASL, SD-pCASL,
and 15O-water from (top) one patient (svFTD2) and (bottom) averaged
over all control participants.
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3.3.3
3.3.3.1

Regional Hypoperfusion Detected by PET and MRI
Qualitative Agreement of Hypoperfusion Maps

Example hypoperfusion maps detected by FL_TE-pCASL, SD-pCASL, and

15

O-

water for aCBF and rCBF are shown in Figure 3.2. In patients with bvFTD (n = 2), all
techniques detected regional hypoperfusion in the inferior and anterior temporal pole,
superior and middle frontal gyrus, frontal pole and anterior cingulate. In addition, the
pCASL sequences detected hypoperfusion in the insula bilaterally. For nfPPA (n = 2), all
techniques identified left lateralized hypoperfusion in the temporal gyrus, insula, frontal
pole and perisylvian area. Inferior regions of the frontal pole showed bilateral
hypoperfusion by 15O-water, whereas SD-pCASL primarily detected hypoperfusion on the
left side. Only FL_TE-pCASL detected hypoperfusion in the right thalamus and caudate.
For PSP (n = 2), hypoperfusion was detected in the midbrain, inferior frontal gyrus, and
precuneus by all techniques. SD-pCASL and

15

O-water also identified regional

hypoperfusion in the anterior cingulate and superior frontal gyrus. Finally, asymmetric
hypoperfusion in the temporal lobe was identified by all techniques in patients diagnosed
with svFTD (n = 2). 15O-water and SD-pCASL identified hypoperfusion bilaterally, with
greater hypoperfusion on the left, whereas FL_TE-pCASL only identified hypoperfusion
on the right side.
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Absolute Perfusion
FL-pCASL

SD-pCASL

15O-water

Relative Perfusion
Overlap

FL-pCASL

SD-pCASL

15O-water

Overlap

bvFTD

nfPPA

PSP

svFTD

Figure 3.2: Regional hypoperfusion detected by FL_TE-pCASL, SDpCASL, and

15O-water

for one patient from each of the FTD subtypes

and PSP. Images are in radiological orientation.

Generally, similar regions of hypoperfusion were identified in the rCBF images and
there was no difference in the volume of hypoperfusion clusters compared to aCBF.
However, greater variability across patients was observed after normalisation. Specifically,
15

O-water and SD-pCASL both showed a 3-to-14 fold increase in hypoperfused voxels in

3 patients (1 nfPPA, 2 svFTD), while the opposite, a 3-to-9 fold decrease, was found in 3
patients (2 bvFTD, 1 PSP) and minimal change (1.4 decrease to 1.1 fold increase) in the
remaining two (1 nfPPA, 1 PSP). FL_TE-pCASL showed similar trends, except for a much
greater increase for one svFTD patient.
Larger regions of hypoperfusion tended to be detected by PET; however, only cluster
sizes detected by FL_TE-pCASL were significantly smaller. On average, SD-pCASL and
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FL_TE-pCASL detected 20.4 ± 38.2 and 21.3 ± 52.9% smaller volumes, respectively,
compared to the aCBF from

15

O-water and 8 ± 37.5 and 41.9 ± 40.6% smaller volumes,

respectively, than the 15O-water rCBF images. However, 44% more hypoperfused voxels
were detected in the SD-pCASL rCBF images for the two bvFTD patients compared to
15

O-water.

3.3.3.2

Quantitative Agreement of Hypoperfusion Maps

Good agreement between regional hypoperfusion detected by 15O-water and pCASL
was found in terms of both aCBF and rCBF. This observation was confirmed by the
sensitivity and specificity calculations for SD-pCASL; 70% and 78%, respectively, for
aCBF and 73% and 74%, respectively, for rCBF. Regional hypoperfusion detected by 15Owater and FL_TE-pCASL using aCBF also showed good sensitivity (71%) and specificity
(73%). However, the sensitivity decreased to 43% for rCBF while the specificity (71%)
remained within a similar range.
The percentage of overlapping, adjacent and isolated voxels identified by SD-pCASL
and FL_TE-pCASL relative to 15O-water are summarized in Table 3.2. SD-pCASL had a
similar proportion of overlapping and adjacent voxels, whereas FL_TE-pCASL had a
smaller portion of overlapping and greater fraction of adjacent voxels. The proportions
identified by SD-pCASL with rCBF were not different from those identified with aCBF.
With FL_TE-pCASL, intensity normalization resulted in an increase (p<0.05) in adjacent
voxels only. For most patients either an increase or small decrease in the percentage of
common voxels was found after intensity normalization (ns) (Table 3.2). However,
normalization caused a substantial decrease in the proportion of voxels common to PET
and SD-pCASL for patients with bvFTD (41 and 74%), and one patient with PSP (36%).
A similar trend was observed with FL_TE-pCASL.
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Table 3.2: Summary of overlap analysis (expressed as a percent) and
Jaccard similarity index of hypoperfusion detected by SD-pCASL and
FL_TE-pCASL

15O-water

PET. Comparison was conducted using

absolute and relative CBF.
SD-pCASL
Absolute CBF
bvFTD1
bvFTD2
nfPPA1
nfPPA2
PSP1
PSP2
svFTD1
svFTD2
svFTD3
Mean ± SD

Overlap

Adjacent

Isolated

Jaccard

32
55
44
27
23
15
59
83
51
43.4 ± 21.3

68
45
54
32
76
80
32
16
48
50 ± 21.8

0
0
3
41
0
5
9
1
1
6.5 ± 13.2

0.2
0.36
0.21
0.12
0.14
0.09
0.05
0.28
0.37
0.2 ± 0.12

Relative CBF
bvFTD1
bvFTD2
nfPPA1
nfPPA2
PSP1
PSP2
svFTD1
svFTD2
svFTD3
Mean ± SD

Overlap

Adjacent

Isolated

Jaccard

19
15
43
35
25
10
68
80
43
37.5 ± 24

75
72
56
51
74
72
31
19
46
55.2 ± 20.4

6
13
1
14
0
19
1
1
11
7.3 ± 7.1

0.12
0.1
0.21
0.19
0.15
0.05
0.25
0.38
0.25
0.19 ± 0.1

87

FL_TE-pCASL
Absolute CBF
bvFTD1
bvFTD2
nfPPA1
nfPPA2
PSP1
PSP2
svFTD1
svFTD2
svFTD3
Mean ± SD

Overlap

Adjacent

Isolated

Jaccard

32
44
21
12
19
8
76
17
40
29.9 ± 21.3

68
56
78
26
78
90
24
26
60
56.2 ± 25.2

0
0
1
62
3
2
0
56
0
13.9 ± 25.6

0.18
0.27
0.08
0.05
0.1
0.05
0
0.04
0.24
0.11 ± 0.1

Relative CBF
bvFTD1
bvFTD2
nfPPA1
nfPPA2
PSP1
PSP2
svFTD1
svFTD2
svFTD3
Mean ± SD

Overlap

Adjacent

Isolated

Jaccard

10
4
22
29
22
2
41
46
22
22 ± 15.3

86
73
75
60
77
84
53
49
65
69.3 ± 13

4
23
2
11
2
14
6
5
12
8.8 ± 7.1

0.04
0.02
0.06
0.11
0.09
0.01
0.05
0.1
0.05
0.06 ± 0.04

Compared to controls, perfusion by 15O-water in patients was significantly lower in
most FTD-specific ROIs (7 of 12) (Figure 3.3).
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Figure 3.3: Regional perfusion measured by FL_TE-pCASL, SDpCASL, and

15O-water.

Boxplots are grouped as patient and controls,

and the colored points represent the diagnosis. Significance levels are
denoted by: * (p<0.05), ** (p<0.001), *** (p<0.0001).

There was good agreement with SD-pCASL and FL_TE-pCASL; of the regions with
significantly lower perfusion in patients, 5 were common to SD-pCASL and 6 to FL_TEpCASL. All techniques showed no difference in perfusion between patients and controls
in the occipital lobe, midbrain, and orbitofrontal gyrus. Regional perfusion by FL_TEpCASL and SD-pCASL tracked well with 15O-water (Figure 3.4) as indicated by the strong
correlation (R > 0.75) in all regions, except for the supplementary motor area (Table 3.3).
Additionally, most regions showed little proportional bias (Figure 3.5, S Figure 3.1).
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Figure 3.4: Comparison of ROI-averaged perfusion estimates from
(blue)

15O-water

and SD-pCASL, (red)

15O-water

and FL_TE-pCASL.

Symbol shapes listed in the legend indicate FTD subtype. The dashed line
represents the line of unity.
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Table 3.3: Linear regression intercept, slope, and correlation coefficient
for comparing perfusion by (1) SD-pCASL and
FL_TE-pCASL and

15O-water

15O-water,

and (2)

in FTD-related ROIs and the occipital

gyrus as a reference region.
SD-pCASL
Region

Intercept

Slope

FL_TE-pCASL
R

Intercept

Slope

R

Amygdala

13

0.53

0.84

28

0.43

0.66

Anterior Cingulate

18

0.54

0.91

23

0.53

0.87

Inferior Frontal Gyrus

15

0.86

0.88

12

0.96

0.93

Insula

18

0.55

0.86

20

0.59

0.86

-5.4

0.72

0.78

-0.47

0.81

0.88

Middle Temporal
Gyrus

16

0.79

0.86

16

0.88

0.95

Orbitofrontal Gyrus

10

0.83

0.85

8.3

0.93

0.87

Precuneus

2.2

1

0.93

-1.3

0.99

0.91

Superior Frontal
Gyrus

14

0.72

0.90

21

0.66

0.80

Superior Temporal
Gyrus

6.9

1.1

0.93

7.3

1.1

0.90

Supplementary Motor
Area

13

0.71

0.55

14

0.62

0.50

Temporal Pole

12

0.88

0.89

30

0.78

0.59

Occipital Gyrus

-3.5

1.3

0.85

-4.6

1.2

0.82

Midbrain
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Figure 3.5: Bland-Altman plots showing agreement between regional
perfusion measured by SD-pCASL and

15O-water.

The solid black line

represents the average difference, and dashed black lines represent the
95% confidence interval.

3.4 Discussion
This study assessed in FTD and related disorders the concordance of regional
hypoperfusion identified by pCASL relative to PET using 15O-water, the gold standard for
imaging perfusion. To appreciate the regional contrast, all perfusion images were
normalized to global CBF measured by PC MRI, which was 41 ± 8.6 ml/100g/min across
patients and 48.1 ± 7.7 ml/100g/min in controls. The latter is consistent with previous
reports involving older populations [10,44]. SD-pCASL and

15

O-water CBF maps had

similar resemblance (Figure 3.1), although greater grey to white matter contrast was
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observed in the PET images (2.7 ± 0.3) compared to pCASL (1.5 ± 0.2), similar to previous
studies [45–49]. This difference is most likely related to the limitation of ASL to accurately
measure white-matter perfusion due to longer transit times [45,50]. Another difference was
the higher CBF values obtained with 15O-water in sublobar regions such as the amygdala
and insula. On average 15O-water values were 25 ± 17% higher than the corresponding SDpCASL values (Figure 3.1). ASL has been shown to underestimate perfusion in these
regions [47,51], while PMRFlow can overestimate CBF due to neglecting blood volume
signal contributions [30]. However, these discrepancies in absolute CBF between

15

O-

water and pCASL are less important for the case-control analysis used to detect regional
hypoperfusion since this method only depends on changes in regional CBF. Similarly, a
recent study reported no significant difference in CBF changes measured by pCASL and
PET during an acetazolamide challenge despite discrepancies in absolute CBF [46]. The
strong correlation between regional perfusion by pCASL and 15O-water (R = 0.85 ± 0.1)
demonstrates that the perfusion changes from the two methods tracked well (Table 3.3).
Furthermore, these results are within the range reported in a previous study that assessed
agreement between ASL and 15O-water in a population of young healthy participants (R =
0.61 - 0.87) [45].
Both 15O-water and SD-pCASL detected hypoperfusion in regions previously shown
to have hypometabolism (Figure 3.2) [52–55]. Similar to previous studies [22,56], the
extent and intensity of clusters detected by 15O-water tended to be larger – on average SDpCASL detected a 20 ± 38% smaller volume of hypoperfusion – suggesting PET had
greater sensitivity. Anatomical regions associated with the overlapping clusters’
coordinates were in regions known to be associated with each FTD subtype. Ninety-three
percent of hypoperfused voxels identified by SD-pCASL were either overlapping with
(43%) or adjacent to (50%) voxels identified by 15O-water, and less than 7% of voxels were
found in isolated clusters. This is in agreement with the sensitivity/specificity analysis:
70% of hypoperfused ROIs and 78% of ROIs with normal perfusion identified by pCASL
were common to 15O-water. In contrast, the Jaccard similarity index, which is a commonly
used imaging metric, did not adequately capture the similarities (Table 3.2). This
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discrepancy is likely related to the large proportion of adjacent, rather than overlapping,
voxels when comparing hypoperfusion maps generated by

15

O-water and SD-pCASL.

Even for the svFTD patient shown in Figure 3.2, in which there was an 83% overlap
between 15O-water and pCASL clusters, the Jaccard index was 0.28.
Unexpectedly, normalizing by whole-brain CBF caused considerable variability in
terms cluster size of detected regional hypoperfusion (Figure 3.2). Some patients showed
the expected increase (e.g. svFTD) or minimal change (e.g. PSP and nfPPA), while others
showed a decrease (e.g. bvFTD, PSP). This last group highlights a potential challenge
associated with assessing relative perfusion changes. Global normalization is intended to
remove between-subject variations, thereby allowing for a more sensitive assessment of
regional hypoperfusion. However, normalization can diminish sensitivity to regional
perfusion deficits if global CBF is significantly reduced by widespread disease effects [57].
This is illustrated by the bvFTD patients for whom approximately 25% of the whole brain
was significantly hypoperfused. Other reference regions were investigated for the bvFTD
patients (specifically the occipital lobe and cerebellum), but the rCBF hypoperfusion maps
remained relatively sparse (data not presented). These results highlight the potential benefit
of quantitative imaging for assessing regional hypoperfusion.
FL_TE-pCASL also showed good agreement with 15O-water (sensitivity = 71% and
specificity = 73%). In addition, there was good correlation between regional perfusion
estimates from the two methods (R = 0.81 ± 0.14 (Table 3.3)). Unlike SD-pCASL,
perfusion in the amygdala and insula regions were not significantly lower than the CBF
estimates from

15

O-water, demonstrating the added value of accounting for transit time

differences. Despite these findings, the overlap between

15

O-water and FL_TE-pCASL

hypoperfusion maps had 30% fewer voxels compared to overlap between

15

O-water and

SD-pCASL (Table 3.2). In addition, intensity normalization reduced the sensitivity by
roughly a half due to the decrease in the already small cluster sizes. Although FL_TEpCASL was shown to have good sensitivity for detecting perfusion changes related to
Moya-Moya disease [51], the hypoperfusion clusters detected in the current study appeared
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sparce and with poorer overlap with 15O-water maps (Figure 3.2). It should be noted that
the FL_TE-pCASL consisted of fewer averages than SD-pCASL, which could have
reduced the sensitivity, making it more challenging to detect subtle perfusion changes
related to dementia. Nevertheless, the good correlation with 15O-water in terms of regional
perfusion (Figure 3.4, S Figure 3.1) shows the promise of FL_TE-pCASL and the value of
optimizing labeling parameters for future dementia studies.
While the results of this study highlight the promise of pCASL for detecting regional
hypoperfusion related to FTD subtypes, there are a few limitations. First, data were
acquired from a small sample, with only 2-3 participants per subtype. Despite the small
sample size, there was good consistency in terms of regional hypoperfusion identified
within each subtype by PET and MRI. Second, the acquisition time for SD-pCASL was
closer to 10 min, rather than the recommended 5 min[18]. A longer scan time was chosen
to improve the signal-to-noise ratio; however, it increases the risk of motion artefacts. The
use of a labeling sequence that included background suppression and careful attention to
minimizing head motion during imaging were implemented to minimize potential motion
artefacts. Finally, partial volume correction was not applied to the perfusion images as this
step is not commonly used in clinical practice. Brain atrophy likely contributed to the
hypoperfusion detected by PET and pCASL, although a previous study reported similar
perfusion differences between dementia patients and controls with and without partial
volume correction [10].

3.5 Conclusion
The present study demonstrates the potential of pCASL for assessing regional
hypoperfusion related to FTD subtypes and PSP. Direct comparison of MRI and PET
perfusion revealed that although 15O-water showed greater sensitivity, as indicted by larger
clusters, SD-pCASL and FL_TE-pCASL identified hypoperfusion in similar regions, with
the former showing strong agreement with the 15O-water results. Although rCBF and aCBF
showed no significant differences in terms of spatial overlap and metrics of agreement with
PET, rCBF showed considerable variability across subtypes, indicating that care must take
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when selecting a reference region. These results support the use of pCASL as a costeffective alternative to PET for assessing regional perfusion deficits associated with FTD.

Supplemental Figures

S Figure 3.1: Bland-Altman plots showing the regional agreement
between perfusion measured by FL_TE-pCASL and 15O-water. The solid
black line represents the average difference, and dashed black lines
represent the 95% confidence interval
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Chapter 4

4

Sensitivity of Arterial Spin Labeling for Characterization
of Longitudinal Perfusion Changes in Frontotemporal
Dementia and Related Disorders

4.1 Introduction
Frontotemporal dementia (FTD) and related disorders comprise a clinically and
pathologically heterogeneous group of neurodegenerative disorders that are characterized
by progressive atrophy of the frontal and temporal lobes with relative sparing of the
posterior cerebral regions, and abnormal molecular accumulations, mostly commonly of
tau or TDP-43 [1]. FTD is the second most common form of early onset dementia, with
the greatest prevalence among individuals between 45 – 64 years of age [2]. FTD is highly
heritable, with up to 40 percent of cases considered hereditary, and ~15% autosomal
dominantly inherited [3]. Advances in the understanding of the link between genetic factors
and the underlying pathophysiology [4,5], and subsequently, the development of candidate
disease modifying treatments, have stimulated the need for efficient tools to assess
treatment efficacy [6].
Longitudinal neuroimaging studies can provide insight into therapeutic efficacy and
characterize natural disease trajectory, which could increase the possibility of
presymptomatic intervention. The majority of studies assessing longitudinal brain function
in FTD have focused on assessing tissue volume loss by structural magnetic resonance
imaging (MRI)[7–9] or regional glucose hypometabolism by

18

F fluorodeoxyglucose

(FDG) positron emission tomography (PET)[10–12]. While these approaches are used
diagnostically, for longitudinal imaging, structural changes are subtle at the early disease
stage and PET imaging is expensive and access limited [13–15].
Due to the coupling of perfusion and metabolism, an attractive alternative to FDG
PET is the MRI-based perfusion imaging technique, arterial spin labeling (ASL)[13,16]. In
FTD, perfusion changes precede structural findings, with reduced frontal and temporal
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cerebral blood flow (CBF) indexed by ASL in presymptomatic FTD mutation carriers
[17,18] as well as symptomatic FTD[14] . Furthermore, longitudinal reductions in
perfusion by ASL have been detected in FTD patients[19] and are associated with clinical
measures of cognitive decline [20], highlighting the potential for ASL for longitudinal
assessments. However, despite that perfusion is one of the earliest changes in pathological
aging [18,21], beyond the aforementioned studies, there are few reports in the literature
investigating the stability of ASL for longitudinal imaging of FTD patients and no studies
assessing the sensitivity of ASL for detecting longitudinal perfusion changes in FTD
patients.
In comparison to young healthy populations where ASL shows good reliability and
reproducibility [22–24], perfusion measurements among elderly populations can be
challenging due to reduced signal to noise ratio (SNR) and potential vascular changes
[25,26]. With age, the brain’s major feeding vessels become tortuous and the prevalence
of stenosis increases. These factors can result in underestimated CBF due to increases in
the arterial transit time (ATT) – i.e., the time required for labeled water to travel from the
labeling site to brain tissue – greatly reducing the sensitivity of ASL to detect clinically
relevant perfusion changes [27]. Furthermore, by collecting data on different days, sources
of variation attributed to repositioning and differences in resting perfusion between days
can introduce error that can confound measurement of longitudinal change. Establishing
the magnitude of perfusion changes that can be reasonably detected among older control
and patient populations would help address the influence of sources of between scan
variability [28], namely, transit time and repositioning errors, as well as day-to-day
fluctuations in CBF.
The primary aim of this study was to assess the sensitivity of ASL for detecting
longitudinal changes in perfusion among patients with FTD using optimized parameters
based on the ASL white paper [29]. To assess sources of variability, reproducibility, and
reliability of single delay pseudo continuous ASL (SD-pCASL) were assessed for sameday scans and scans collected during sessions separated by a month. A relatively short
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between-session period (4 weeks) was selected to avoid disease-related brain atrophy or
pathological changes in the patient population. Differences in variability between the
aforementioned scan separations reflects error due to repositioning and differences in
resting perfusion between sessions. To assess the effects of day-to-day changes in
perfusion, variability was assessed for absolute and relative perfusion. Power analysis was
conducted to determine the number of participants required to detect clinically relevant
longitudinal perfusion changes. The influence of ATT on the longitudinal reproducibility
of CBF, was determined by quantifying the between-session variability of ATT measured
by a low-resolution (LowRes-pCASL) sequence using multiple inversion times. Given that
visual assessment remains a primary source of scan interpretation, a voxel-by-voxel
approach was implemented to visualize the spatial distribution of variability and,
furthermore, to identify regions where longitudinal changes would be more challenging to
detect. As previous studies have suggested that time-encoded multi-delay sequences can
improve SNR and temporal efficiency [30–32], a secondary aim was to compare perfusion
and transit times measured by SD-pCASL and LowRes-pCASL, respectively, to
Hadamard-encoded multi-delay sequences.

4.2 Materials and Methods
4.2.1

Participants

This study was approved by the Western University Health Sciences Research Ethics
Board and was conducted in accordance with the Declaration of Helsinki ethical standards.
Participants provided written informed consent in compliance with the Tri-Council Policy
Statement of Ethical Conduct for Research Involving Humans.
Fourteen neurologically healthy controls and ten patients with FTD or progressive
supra-nuclear palsy (PSP) were enrolled in the study. Patients were recruited through the
Cognitive Neurology and Aging Brain Clinic at Parkwood Hospital (St Joseph’s Health
Care London) and controls were recruited through advertisements and the clinic’s
volunteer pool. Studies were performed between November 2019 and December 2020. The
patient cohort consisted of individuals meeting the consensus criteria for probable or
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definite FTD or PSP; specifically, behavioural variant (bvFTD) [33], semantic variant
(svFTD) [34], non-fluent primary progressive aphasia (nfPPA) [34], and PSP [35].
Exclusion criteria included (1) any significant neurologic disease other than suspected
FTD, (2) presence of pacemakers, aneurism clip, artificial heart valves, ear implants, metal
fragments or foreign objects that would preclude MRI participation, (3) major depression,
bipolar disorder, psychotic features, or behavioural problems, and (4) any significant
systemic illness or unstable medical condition. Diagnostic evaluations were performed by
a clinical neurologist (E.F) based on clinical evaluation, neurocognitive testing, clinical
MRI brain imaging, and genetic testing.

4.2.2

Measures

Patients completed a battery of validated cognitive tasks assessing domains of
cognition including the Addenbrooke's Cognitive Examination (ACE-III American
Version A) (NeurRA; www.neura.edu.au) [36], Mini-ACE (M-ACE; NeurRA), Boston
Naming Test Second Edition Short Form (BNT) [37], Short Form Geriatric Depression
Scale (GDS) [38]. Study partners completed ratings of participants’ symptoms and
behaviour using the Cambridge Behavioural Inventory (CBI) [39], Neuropsychiatric
Inventory (NPI) [40], Frontal Behavioural Inventory (FBI) [41], and Cornell Scale for
Depression [42] during one of their two visits.

4.2.3

Imaging

All MRI examinations were performed on a 3T Siemens Biograph mMR scanner
using a 12-channel head coil. Participants were required to abstain from caffeine 8 hours
before each scan. Each participant was scanned on two occasions separated by
approximately 4 weeks. Repeat scans were scheduled at a similar time of day to minimize
time-of-day effects [22]. SD-pCASL data were acquired twice during each imaging session
for a total of 4 scans. This protocol allowed for the assessment of two types of withinsubject variability: within-session, representing fluctuations in same-day measurements,
and between-session, representing the variability in measurements separated by 4 weeks.
LowRes-pCASL was performed once in each session to assess between-session variability
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in transit times. Hadamard-encoded sequences were acquired once during one of the two
imaging sessions. All scans were performed at rest with the participants awake in the
scanner. To improve compliance, participants watched a low cognitive demand movie [43].
Each scanning session included a T1-weighted magnetization-prepared rapid acquisition
gradient echo (MPRAGE) sequence with repetition time (TR)/echo time (TE): 2000/2.98
ms, voxel size: 1 mm isotropic, field of view (FOV) 256 x 256 x 176 mm3, scan time: 4:38
minutes.

4.2.3.1

Single Delay pCASL

Single delay pCASL data were acquired with a 4-shot 3D gradient and spin echo
(GRASE) readout [44]; TR/TE: 4500/22.14 ms, voxel-size: 4 mm isotropic, FOV: 256 x
256 x 128 mm3, label-control pairs: 8, bandwidth: 2298Hz/Px, 1 preparing scan, scan time:
4:53 minutes. A post-labeling delay (PLD) of 2000 ms and label duration (LD) of 1800 ms
were used as recommended by the ASL consensus paper [29]. For all pCASL sequences,
two inversion pulses were used to null components with relaxation times T1 = 700 and
1400 ms [44]. To maintain a consistent acquisition protocol, these parameters were used in
both patients and healthy controls, despite the shorter recommended PLD for healthy
controls. An equilibrium magnetization image (M0) was acquired to convert perfusionweighted images into physiological units of blood flow. Imaging parameters were identical
to the pCASL acquisition except for a TR of 7000 ms and no background suppression or
labeling. Since the feeding arteries are often tortuous in elderly populations [27,45], the
labeling plane offset was manually adjusted for each participant to ensure the labeling plane
was straight and parallel to the vessels. A 3D time-of-flight MRI angiography (TR/TE:
22.0/3.75 ms, voxel-size: 0.3 x 0.3 x 1.5 mm3, FOV: 263 x 350 x 350 mm3, 4 slabs, 30
slices per slab, scan time: 4:23 minutes) was acquired to identify the major arteries for
labeling plane preparation. The offset ranged between 90 and 125 mm from the center of
the imaging slab. The same labeling plane was used for all subsequent ASL sequences.
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4.2.3.2

Low-Resolution Multi-Delay pCASL

LowRes-pCASL data were acquired with a single-shot 3D GRASE readout: TR/TE:
5500/20.68 ms, voxel-size: 7.8 mm isotropic, FOV: 255 x 500 x 125 mm3, PLDs: 700,
1300, 1900, 2500, 3000 ms, LD: 2000 ms, bandwidth: 2298Hz/Px, 1 preparing scan. Four
label-controls pairs were acquired for each PLD for a total scan time of 4:10 minutes. These
images were acquired to map the ATT.

4.2.3.3

Hadamard Encoded pCASL

With Hadamard-encoded ASL, the pCASL bolus is divided into several uniquely
encoded label and control sub-boluses where their ordering corresponds to a Hadamard
matrix [30,46]. Two variations of this sequence were employed: (1) conventional timeencoding (conv_TE-pCASL), where the sub-boluses are divided into blocks of equal
length, and (2) free-lunch time-encoding (FL_TE-pCASL), where the labeling period is
similar in length to the SD-pCASL sequence; however, the traditional PLD is replaced with
time-encoding blocks. By linearly combining the images, perfusion-weighted images at
different PLDs were extracted.
Hadamard-encoded data were acquired with a 2-shot 3D-GRASE readout sequence
with 8 encoding steps, TR/TE: 5500/21.22 ms, voxel-size: 5 mm isotropic, FOV: 320 x
215 x 120 mm3, bandwidth: 2894 Hz/Px, slice partial Fourier: 6/8, phase partial Fourier:
6/8, 4 measurements per PLD. For conv_TE-pCASL, the sub-bolus duration was 400 ms
and effective PLDs were 2600, 2200, 1800, 1400, 1000, 600, 200 ms. For FL_TE-pCASL,
the sub-bolus duration was 250 ms, a free-lunch LD of 2000 ms, and PLD = 200 ms.
Altogether, this corresponded to PLD1/LD1: 1700 ms/2000 ms, LD2-7: 250 ms, PLD2-7:
1450, 1200, 950, 700, 450, 200 ms. The total scan time for both sequences was 5:52
minutes. An M0 image was acquired with identical parameters except no background
suppression or labeling.
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4.2.4

Image Processing

Image analysis was performed with SPM12 (http://www.fil.ion.ucl.ac.uk)[47],
Oxford Centre for Functional MRI of the Brain (FMRIB)'s software library (FSL 6.0.1)
[48], and in-house MATLAB scripts (MATLAB 2018a, The MathWorks, Natick, MA).
Prior to any analysis, all images were manually reoriented to the axis of the anterior and
posterior commissure. T1-weighted images from each session were coregistered and
averaged using SIENA [49]. By transforming the two structural images into a halfway
space, both images undergo the same resampling steps, thereby reducing potential
interpolation bias. The resulting structural images were processed using the fsl_anat
pipeline to generate bias-corrected, skull-stripped, tissue-segmented, and spatially
normalized structural images, as well as a normalization matrix [50]. Grey and white matter
masks were generated by thresholding the respective tissue segmented images to include
voxels with tissue probabilities greater than 0.8.

4.2.4.1

Single Delay pCASL

M0 images from the first and second imaging session were realigned to their mean
and co-registered to the T1-weighted images. Using SPM12, raw SD-pCASL data were
motion corrected, registered to the mean M0, and pairwise subtracted. Poor quality
difference images were identified using ENABLE[51], an automated sort/check algorithm.
Briefly, each difference image was scored based on a linear combination of ASL quality
features: temporal SNR, detectability metric (proportion of grey-matter voxels with signals
significantly greater than zero), temporal contrast-to-noise ratio, and spatial coefficient of
variation. Image volumes that did not meet the quality criterion were removed. Perfusion
was quantified using the Oxford ASL toolbox (oxasl) which uses Bayesian inference to
perform kinetic modeling and spatial regularization [52,53]. The incorporation of these
spatial and biophysical priors reduces the uncertainty of model parameters by encoding
realistic assumptions and accounting for natural variability in the model parameters. A
standard well-mixed single compartment model was applied to the motion-corrected and
filtered perfusion-weighted images [54]. Model parameters were based on the guidelines
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of the ASL consensus paper [29]: T1 of tissue = 1300 ms [55], T1 of arterial blood = 1650
ms [56], labeling efficiency = 0.85 [57], blood-brain partition coefficient = 0.9 ml/g [58].
Registration between perfusion/transit time and structural images was carried out using
boundary-based registration [59]. Images were normalized to the MNI template by
applying the transformation parameters generated by fsl_anat using a non-linear image
registration tool (FNIRT [60]) and smoothed by a 6-mm Gaussian filter.

4.2.4.2

Multi-Delay pCASL

Raw LowRes-pCASL data were motion corrected and pairwise subtracted using
SPM12. Data were fit to the general kinetic model with oxasl to extract the ATT [52]. The
single compartment model with no dispersion was fit using the aforementioned SD-pCASL
model parameters. ENABLE was implemented to remove low quality difference images.
Hadamard-encoded data were processed in a similar manner except no motion correction
was applied and instead of pairwise subtraction, the Hadamard transform with Walsh
ordering was applied to generate images for each label/sub-bolus [30]. Both perfusion and
ATT maps were generated from the Hadamard sequences. All resulting data were
normalized to the MNI template and smoothed as described previously.

4.2.5

ROI Analysis

Region of interest (ROI) analysis was performed to assess regional reproducibility of
SD-pCASL and compare CBF and ATT measured by the different sequences. This was
performed in grey and white matter as well as regions commonly associated with FTD;
namely, the orbitofrontal gyrus, inferior frontal gyrus, superior frontal gyrus, insular
cortex, amygdala, temporal pole, and occipital gyrus (as a reference region) [61]. FTDspecific ROIs were generated by combining regions from the automated anatomical
labeling

(aal)

atlas

in

WFU
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4.2.6

Statistics

Statistical analysis was performed using R (R Core Team 2013, https://www.rproject.org/) and MATLAB. Variance components were estimated using a random effects
model that employed restricted maximum likelihood. The variance components were
estimated according to the following model [62]:
𝐶𝐵𝐹𝑖𝑗𝑘 = 𝜇 + 𝑈𝑖 + 𝑉𝑖𝑗 + 𝜀𝑖𝑗𝑘

(4.1)

This model was fit with perfusion (CBFijk) for the ith subject, jth session, and kth run,
as the response variable and random effects for subject (U) and subject-by-session (V). The
grand mean is represented by  and  is the residual. By nesting session within subject,
sessions were uniquely coded to each subject. Variance was decomposed into 3
components: variance between subjects, variance between sessions and a residual variance
component due to random error. This residual term is an estimate of variance that would
result from the two repeat scans within a single session for a given participant. Each
variance component indicates the magnitude of variance that the respective individual
factor contributes. The within-subject variance (i.e., sum of the between-session and
within-session variances) represents the variance in perfusion images acquired during
sessions collected 4 weeks apart in a given participant. This estimate reflects the variance
encountered in a study in which a participant is scanned once in each session.
Reproducibility, hereby defined as the variability in repeat measurements, was
quantified by the coefficient of variation (CV). Between-subject and within-subject (i.e.
within/between-session) CV were calculated by dividing the respective standard deviation
(σ) by the mean (μ):
𝐶𝑉 =

𝜎
∗ 100%
𝜇

(4.2)

The intraclass correlation coefficient (ICC) was used to assess reliability [63]. While
the ICC can be interpreted as the variance in the outcome variable that is accounted for by
the grouping variable (e.g. subjects), an alternate interpretation is the expected correlation
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between randomly drawn units from the same group [64]. In the context of the current
study, we implement two variants of the ICC; ICCbetween, defined as the expected
correlation in CBF among sessions for a randomly selected subject and ICCwithin, defined
as the estimated correlation in CBF from runs within the same session for a randomly
selected subject. These metrics of reliability were assessed by:
𝐼𝐶𝐶𝑏𝑒𝑡𝑤𝑒𝑒𝑛 =

𝐼𝐶𝐶𝑤𝑖𝑡ℎ𝑖𝑛 =

2
𝜎𝑠𝑢𝑏𝑗𝑒𝑐𝑡
2
𝜎𝑡𝑜𝑡𝑎𝑙

(4.3)

,

2
2
𝜎𝑠𝑢𝑏𝑗𝑒𝑐𝑡
+ 𝜎𝑠𝑒𝑠𝑠𝑖𝑜𝑛−𝑏𝑦−𝑠𝑢𝑏𝑗𝑒𝑐𝑡
2
𝜎𝑡𝑜𝑡𝑎𝑙

.

(4.4)

Total variance was defined as the sum of the individual components:
2
2
2
2
𝜎𝑡𝑜𝑡𝑎𝑙
= 𝜎𝑠𝑢𝑏𝑗𝑒𝑐𝑡
+ 𝜎𝑠𝑒𝑠𝑠𝑖𝑜𝑛−𝑏𝑦−𝑠𝑢𝑏𝑗𝑒𝑐𝑡
+ 𝜎𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙

(4.5)

ICC values range between 0 and 1, where results were interpreted based on the
following guidelines [65]: poor (< 0.4), fair (0.41-0.59), good (0.6 – 0.74), and excellent
(> 0.75). Reproducibility and reliability were calculated on a voxel-by-voxel basis to
visualize the spatial distribution.
Based on the variance in CBF derived by the random effects model, power
calculations were performed to estimate the number of participants (N) required to detect
a given change (∆) in perfusion between sessions. This was computed by the following
equation:
2𝜎 2 (𝑍1−𝛼 + 𝑍1−𝛽 )
𝑁 =
∆2

2

(4.6)

where 2 represents the within-subject variance, Z1- is the Z-score for the
significance criterion, and Z1- is the z-score for the statistical power. Variance was
determined based on the average of the two runs in each session, which is equivalent to
one 10-minute scan. This was performed to minimize the effects of within-session
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variability and to reflect the variability observed in a longitudinal clinical study where
multiple runs would not be acquired. The detection power was set to 80% (i.e., Z1- = 0.84)
and the significance level was set to  = 0.05 based on a one-tailed t-test since the primary
focus is on detecting regional perfusion deficits (i.e., Z1- = 1.645). A detectability map
depicting the number of participants required to detect a 10% perfusion change between
sessions was generated to visualize the estimated sample size for ROIs generated using the
aal atlas.
To determine whether there were differences in CBF and ATT among the three ASL
sequences, data were fit to a linear mixed model and an ANOVA used to test for
significance. T-tests were used to assess between-group differences. For all tests p < 0.05
were considered significant. To assess the effect of day-to-day variations, the minimum
detectable difference and reproducibility of SD-pCASL CBF were assessed using absolute
(aCBF) and relative perfusion (rCBF), where relative perfusion was generated by intensity
normalizing by the mean whole-brain CBF. Reliability was only calculated with aCBF,
due to the reduction in between-subject variance after intensity normalization.

4.3 Results
4.3.1

Demographics and Cognitive Measures

Of the fourteen controls and ten patients recruited and screened for the current study,
three patients and one control had missing follow-up data. The final sample of the testretest study included 13 controls and 7 patients. Within-session scans were separated by
approximately 30 minutes, while the average separation between imaging sessions was 26
± 4 days. Data comparing ASL sequences included Hadamard-encoded data acquired in 9
controls and 8 patients. LowRes-pCASL and SD-pCASL data from the corresponding
participants were included in this analysis. Demographic and clinical characteristics of all
the participants are summarized in Table 4.1. As expected, healthy controls scored
significantly higher on all cognitive tests (p<0.05).
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Table 4.1: Summary of demographics and cognitive measures.
Patients

Controls

Demographics
Sex (M:F)
Age

3:5

8:5

68.8 ± 8.8

61.5 ± 9.6

3 svFTD, 2
nfPPA, 2 bvFTD,
1 PSP

Diagnosis

-

Cognitive Measures
N

Score

N

Score

8

54.8 ± 20

13

93.2 ± 3.5§

8
8
8
8
8
8
8

13 ± 7.3
15 ± 2.7
10 ± 6.8
4.6 ± 3.4
12.6 ± 8.4
12.5 ± 2.1
4.3 ± 6.1

13
13
13
13
13
13
11

28.1 ± 2.2§
17.2 ± 1.5§
23.6 ± 2.8§
11.9 ± 2.3§
25.5 ± 1.1§
15 ± 1§
13.8 ± 1.6§

8

3.8 ± 2.3

10

0.8 ± 1§

7

11.6 ± 16

-

-

8

22.1 ± 14.1

-

Cornell (38)

7

6.9 ± 4.7

-

-

Cambridge Behavioural
Inventory Revised (180)

8

41.4 ± 18.7

-

ACE-III Total Score
(American Version A)
Mini-ACE Total Score (30)
Attention (18)
Memory (26)
Fluency (14)
Language (26)
Visuospatial (16)
Boston Naming (15)
Geriatric Depression
Scale (Short Form; 15)
Caregiver Measures
Neuropsychiatric
Inventory Total Score
(144)
FBI Total Score (72)

-

Values are expressed as the mean ± standard deviation. Values in parenthesis represent the
maximum score for each test. T-tests were conducted to test for differences in cognitive measures
among patients and controls. Statistical significance (p < 0.05) is indicated by §

4.3.2

Test-Retest Reproducibility of Single Delay pCASL

Average grey-matter perfusion across all sessions was 68.6 ± 1.7 ml/100g/min in
controls and 65.2 ± 1.72 ml/100g/min in patients. Representative perfusion images from
example control and patient participants for the two sessions are shown in Figure 4.1.
Perfusion maps were scaled to a common range for display purposes. Perfusion maps
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showed the expected contrast between grey and white matter. While overall there was good
agreement within and between sessions, there were noticeable differences in regional
perfusion between sessions in some participants (e.g., reduced frontal perfusion for patient
10 during session 2). To a lesser extent, this phenomenon was also evident in control 1,
session 2.

Figure 4.1: Example control and patient perfusion maps (in relative
units) for each session and run.

4.3.2.1

Voxel-by-voxel Variability

Control and patient CV maps were similar, with both showing increased variance in
white-matter, cerebrospinal fluid, and regions proximal to the brain’s feeding vessels
(Figure 4.2). Following intensity normalization, there was a global decrease in grey-matter
CV in both controls and patients; however, regions of high variability in white-matter and
cerebral spinal fluid remained. In controls, between-subject variability was higher in whitematter, ventricles, and the posterior regions of the brain. Although between-subject
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reproducibility in grey-matter were within a similar range, (21.4% in controls and 25.3%
in patients), in patients, distinct regions of increased variability including the superior
frontal gyrus, cerebellum, brainstem, and the left intra-calcarine cortex were apparent. For
both patients and controls, good-to-excellent reliability was determined for the withinsession comparison, whereas fair-to-good reliability was achieved between sessions. For
all comparisons, participants showed lower reliability in the striatum relative to other
regions. In patients, a clear increase in grey-matter reliability relative to white-matter was
observed, especially between sessions.

Figure 4.2: Coefficient of variation and intraclass correlation coefficient
maps in patients and controls within-session, between-sessions, withinsubject, and between-subjects. Both measures of variability were
calculated for absolute CBF, but only the coefficient of variation for
relative CBF.
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Average voxel-by-voxel within and between-session variability in grey-matter aCBF
were comparable for patients (within-session: 16%, between-session: 10.8%) and controls
(within-session: 13.9%, between-session: 8.3%). Within-subjects variability in grey-matter
was 19.2% and 16.2% in patients and controls, respectively. After intensity normalization,
there was a small decrease in within-session variability (controls: 12.3%, patients: 14.8%),
whereas between-session CV decreased to a greater extent (controls: 6%, patients: 8.5%).
The corresponding within-subject variance were 16.3% and 13.9% in patients and controls,
respectively. Good reliability among same-day scans in both patients (ICCwithin = 0.73) and
controls (ICCwithin = 0.71) was found. Reliability was also good between sessions; however,
there was a moderate decrease for both patients (ICCbetween = 0.62) and controls (ICCbetween
= 0.62).

4.3.2.2

Variability in FTD-specific ROIs

Across FTD-specific ROIs, there were no differences in perfusion between sessions
or runs. Average reliability and reproducibility in FTD-specific ROIs are summarized in
Figure 4.3. The superior frontal gyrus and temporal pole showed a high amount of
variability (CV > 15%) in patients and controls, whereas the orbitofrontal gyrus and
amygdala showed high variability in patients only. Between sessions, CV was higher in
the superior frontal gyrus and amygdala in patients. Intensity normalization resulted in a
significant reduction in between-session CV (p<0.05). With both aCBF and rCBF, withinsession CV was significantly higher than between-session CV (p<0.05). Within-session
reliability was fair to excellent in both patients (range: 0.48 – 0.78) and controls (range:
0.5 – 0.89). Between sessions, there was a significant reduction in reliability for patients
and controls; the majority of regions showed fair reliability; however, as indicated by
ICCbetween < 0.4, in patients, reliability in the amygdala and temporal pole was poor.
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Figure 4.3: (A) Within-session (WS), between-session (BS), and betweensubjects (BSub) reproducibility measured using absolute (ABS) and
relative (REL) perfusion for (top) Controls and (bottom) Patients. (B)
Reliability of within-session and between-session perfusion using
absolute perfusion in (top) Controls and (bottom) Patients.

4.3.3

Detectability

Detectability maps depicting estimated sample sizes required to detect a 10%
decrease in perfusion between sessions using a 10-minute pCASL scan are shown in Figure
4.4. Across ROIs, within-subject variance ranged between 5.1 – 14.5ml/100g/min for
aCBF and 3.5 – 12.1ml/100g/min for rCBF. For FTD-specific ROIs, the number of
participants required was significantly higher in patients (26 ± 14) relative to controls (13
± 5) (p<0.05). This estimate was based on averaging common ROIs on the left and right
hemisphere. After intensity normalization, these values decreased to 10 ± 9 for patients and
5 ± 2 for controls (ns). Although intensity normalization improved regional detectability,
as indicated by significant reduction in estimated sample sizes and the cooler colors in
Figure 4.4, in patients, the lowest sensitivity remained in the frontal lobe and sub-lobar
regions.
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Figure 4.4: Detectability maps indicating the number of participants
required to detect a 10% perfusion change within ROIs.

4.3.4

Perfusion Comparison in Healthy Controls

Perfusion maps averaged over healthy controls and generated by the three pCASL
sequences are shown in Figure 4.5. Each average contains an identical sample of controls.
While all sequences show similarities in contrast and regional distribution between grey
and white matter perfusion, midbrain perfusion appears to be greater in FL_TE-pCASL
and conv_TE-pCASL sequences. Average grey-matter CBF measured by SD-pCASL,
FL_TE-pCASL and conv_TE-pCASL were: 67.7 ± 15, 95.6 ± 21.1, 96.7 ± 25 ml/100g/min
in controls. Perfusion averages within FTD-specific ROIs are shown in Figure 4.6.
Perfusion estimates by the Hadamard sequences had greater between-subject variability
and were consistently higher than SD-pCASL estimates in all regions (p<0.05) except for
the occipital gyrus. Compared to the conv_TE-pCASL, FL_TE-pCASL was significantly
lower in the amygdala, insula, and temporal pole (p<0.05).
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Figure 4.5: Perfusion averaged over healthy controls measured by (A)
single delay pCASL, (B) free-lunch time-encoded pCASL and, (C)
conventional time-encoded pCASL. Note, colour bar has been adjusted
for each image for better visualization.

Figure 4.6: Comparison of CBF by SD-, FL_TE- and conv_TE-pCASL
in grey-matter, white-matter, and a sample of ROIs commonly associated
with FTD. Regional perfusion averages are based on data from healthy
controls only. Outliers are identified by black dots.
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4.3.5

Arterial Transit Time Comparison in Controls and Patients

Figure 4.7 shows ATT maps generated using LowRes-pCASL, FL_TE-pCASL, and
conv_TE-pCASL sequences generated for both controls and patients. All sequences show
similar spatial patterns with shorter transit times near the centre of the major feeding
arteries and increased transit times in the watershed regions. Grey-matter ATT measured
by LowRes-pCASL, conv_TE-pCASL and, FL_TE-pCASL were 1.24 ± 0.16, 1.10 ± 0.08,
and 1.12 ± 0.08 seconds in controls and 1.30 ± 0.11, 1.16 ± 0.05, and 1.17 ± 0.04 seconds
in patients, respectively. For all sequences, ATT measured in patients were not
significantly different from controls. Average ATT values in FTD specific ROIs are shown
in Figure 4.8. Among the three sequences, the only significant differences in transit times
were in the occipital gyrus, orbitofrontal gyrus, and superior frontal gyrus, where the
LowRes-pCASL values were significantly higher than the corresponding conv_TE-pCASL
and FL_TE-pCASL values. ATT CV maps were mostly homogeneous, with some nonspecific spatial patterning (S Figure 4.1). Average between-session CVs in grey-matter
were 17.1 ± 5.9% and 15.2 ± 6.3% in controls and patients, respectively.
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Figure 4.7: Average arterial transit time maps in patients and controls
by LowRes-, FL_TE- and conv_TE-pCASL. Note, colour bar has been
adjusted for each image for better visualization.
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Figure 4.8: Comparison of ATT by LowRes-, conv_TE-, and FL_TEpCASL, in grey-matter, white-matter, and a sample of regions commonly
associated with FTD in controls (top) and patients (bottom). Outliers are
identified by black dots.

4.4 Discussion
Multiple studies have demonstrated the potential of ASL for assessing disease-driven
perfusion changes that differentiate clinical populations as well as presymptomatic
mutation carriers [16,18,61]. Considering that ASL is non-invasive and quantitative, it is
well suited to longitudinal studies aimed at characterizing disease progression and
evaluating treatment efficacy. Toward this goal, the current work focused on evaluating
the reproducibility of an optimized ASL sequence for monitoring long-term changes in
perfusion in FTD patients. As an initial evaluation, this study included patients who met
the consensus criteria for probable FTD or PSP and age-matched controls. Imaging was
performed in two sessions that were separated by four weeks – a period selected to
minimize possible disease-related perfusion changes. Both within- and between-session
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variability was assessed to evaluate the impact of common sources of error associated with
longitudinal studies including head repositioning and day-to-day fluctuations in CBF.
Considering the impact of ATTs on CBF quantification, a second aim was to compare the
performance of SD-pCASL and LowRes-pCASL, in which perfusion and ATT are
measured separately, to Hadamard-encoded sequences that measure both parameters
simultaneously. While the latter methods provide the ability to image faster with superior
SNR, they are more sensitive to motion artifacts. To the best of our knowledge, this is the
first study to perform this comparison in an older population. The main results of the study
showed that (1) test-retest repeatability was similar in the patient group compared to
controls, (2) variations in transit times were not a significant source of error with this
patient population, and (3) perfusion imaging by Hadamard-encoded sequences yielded
systematically higher CBF compared to SD-pCASL but produced similar transit-time
measurements compared to LowRes-pCASL.
Since the role of ASL in assisting with the diagnosis of FTD subtypes is to detect
spatial patterns of hypoperfusion, the current study primarily focused on characterizing
variability on a voxel-by-voxel basis. This approach provided the ability to identify regions
with greater variability, which could make it more challenging to detect perfusion changes
in longitudinal studies. In general, within-subject reproducibility and reliability maps,
shown in Figure 4.2 and summarized in Figure 4.3, for the patient and control groups were
similar. Between-session grey-matter reproducibility and reliability for patients were
similar to values for controls (CV = 10.8% vs 8.3%, ICCbetween = 0.62 vs 0.62, respectively).
Regions with the highest variability (the superior frontal gyrus and temporal pole) were
common to both groups (Figure 4.3), although the CV in dementia-specific ROIs were
significantly lower for controls. Increased variability in the superior frontal gyrus and
temporal pole are likely related to susceptibility artifacts due to brain-air interfaces,
particularly in the patient population where there is greater brain atrophy [66]. Visual
inspection of Figure 4.2 revealed that in both patient and control participants, there was an
imaging artifact in the sub-lobar region that is consistent with signal dephasing due to the
pulsatile flow in the circle of Willis during the GRASE readout. In the patient group, its
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border spread into the amygdala region, explaining the increased variability in this region.
While a segmented sequence was implemented to reduce the effects of T2 decay during
the readout [67], it may be possible to further reduce this artifact by using a variable flip
angle [68,69]. Between-subject reproducibility among patients showed increased CV in the
occipital and posterior regions. While this increase could reflect the disease-driven
heterogeneity in regional hypoperfusion, since these regions are not typically affected by
in FTD and the related disorders, it more likely reflects individual differences due to the
small sample size.
Both the accuracy and precision of ASL-CBF are affected by factors such as its
inherently low SNR, subject motion, sensitivity to transit delays, and labeling efficiency
[23]. In addition to these within-session sources of error, factors that can degrade betweensession reproducibility include repositioning errors and differences in resting perfusion
between scanning sessions [70]. Efforts to minimize these sources of variability include
conducting repeat imaging sessions around the same time of day [22], having participants
avoid substances known to affect CBF (e.g. caffeine) [28], and implementing a preprocessing pipeline, including ENABLE, to ensure the quality of the ASL images and good
registration to the MNI template [51,71]. The similarity of perfusion maps separated by a
month (Figure 4.1) demonstrated the effectiveness of these approaches. Between-session
variability in grey-matter showed good correlation (ICCbetween > 0.6) and good
reproducibility in both patients and controls (CV<11%). With intensity normalization,
there was approximately a 28 and 21% reduction in between-session CV in patients and
controls respectively, highlighting the systemic effect of day-to-day fluctuations in resting
perfusion (Figure 4.2). Together, these results suggest that with good alignment of data
between sessions, and careful control of perfusion modifiers, sources of between-session
variability can be minimized. This is particularly relevant for clinical diagnosis and
management of FTD given that perfusion changes are subtle.
ROI-based between-session reproducibility and reliability across grey-matter for
patients (CV=9.04%, ICCbetween=0.77) and controls (CV=6.5%, ICCbetween=0.77) were
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within the range of previous studies of other causes of dementia. Kilroy et al assessed
reproducibility and reliability of pCASL GRASE in a population of older healthy controls,
and patients with MCI and Alzheimer’s disease[25]. The authors reported a CV of 10.9%
and an ICCbetween of 0.707 among perfusion measurements separated by 4 weeks. Similar
results were observed in different scan separations among young and older participants.
Chen et al reported a CV of 8.5 ± 0.14% for data collected 1 week apart in young healthy
participants [23]; more recently, in a population of adult Latinx participants at risk for
vascular disease, Jann et al. reported a CV of 7% and ICCbetween of 0.84 [72]. The finding
that longitudinal variability of the current implementation of ASL is comparable to, and in
some cases superior to previous studies, supports the potential of ASL as a sensitive marker
of longitudinal perfusion changes.
Metrics of within-session reproducibility and reliability were similar in both patients
and controls (Figure 4.2). In grey-matter, patients and controls CVs were within roughly
14% of each other (i.e. 16% vs 13.8%, respectively) and correlations between repeat
measurements were good (i.e. 0.73 vs 0.71). An unexpected finding was the reproducibility
between sessions was greater than the reproducibility between runs in the same session.
Within-session variance was 64% and 70% of the within-subject variance in patients and
controls. After intensity normalization, these proportions were: 70% and 77% in the two
groups, respectively. This suggests that even after minimizing between-session variance,
within-session variance remained dominant. One possible explanation is that perfusion
modifiers such as arousal and attention could have led to changes in global CBF between
the two runs [28]. As participants acclimatized to the scanner environment, cerebral
perfusion could have decreased considering the two runs were separated by approximately
30 minutes. However, a repeated measures ANOVA confirmed that average grey-matter
perfusion between runs were not significantly different. A more likely explanation is the
inherently low SNR of the ASL sequence. Considering that the ASL signal used to
calculate perfusion is on the order of 1% [29], several tag-control pairs are typically
acquired to improve SNR. In the current study, 8 tag-control pairs were collected in each
run to keep the scan time around 5 minutes, which is typical for clinical studies. However,
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the unexpectedly poor within-session reproducibility indicates that more averages should
be acquired. In order to more accurately characterize perfusion, we recommend a 10minute SD-pCASL scan.
As a means of visualizing the impact of between-session variability on tracking
longitudinal changes in regional CBF, detectability maps were created to show the
predicted sample size that would be required to detect a 10% perfusion change in individual
anatomical regions (Figure 4.4). In light of the unexpectedly high within-session
variability, data from the two runs in each session were combined and within-subject (i.e.
between-session) variance was estimated based on the two resulting 10-minute SD-pCASL
scans. Focusing on FTD-specific ROIs, the predicted sample sizes required for patients
(aCBF = 26 ± 14, rCBF = 10 ± 9) were generally larger than those required for controls
(aCBF = 13 ± 5, rCBF = 5 ± 2). However, this difference only reached statistical
significance for absolute CBF. For both groups, a greater number of participants were
predicted for ROIs in the frontal and occipital lobes, particularly near watershed regions
(Figure 4.4). These findings could be related to differences in labeling efficiency between
sessions. In an effort to maximize labeling efficiency, a time-of-flight image was used to
locate the ideal location for the ASL labeling plane during the first session. Since identical
parameters were repeated during the second session, it is possible that the labeling location
was not ideal, which could influence the image contrast considering the tortuosity of
feeding brain vessels increases with age [73,74]. This variability was observed in both
patients and controls as evident in Figure 4.1 in which control 1 and patient 10 exhibited
reduced frontal perfusion during the second imaging session. Nevertheless, the prediction
that roughly 10 participants would be required to detect a 10% perfusion change in regions
relevant to FTD indicates that with careful parameter selection, the current implementation
of ASL has the sensitivity to detect longitudinal perfusion changes with relatively small
sample sizes. This finding is promising for clinical studies given that FTD is relatively rare
[19], which can make recruitment of large number of patients challenging.
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Since the prevalence of cerebrovascular disease among patients with FTD is low [75–
77], variation in transit times between the different subtypes was not expected, and
therefore, ATT data were averaged across all patient participants. Visual inspection of the
ATT maps averaged across patients shows strong resemblance to the corresponding maps
generated from the controls (Figure 4.7). In addition, average whole-brain ATT values for
controls and patients were not significantly different. Likewise, between-session wholebrain CV for patients (15.2 ± 6.3%) and controls (17.1 ± 5.9%) were similar, and the CV
maps were homogeneous (S Figure 4.1), indicating no regional effects. In contrast to
patients with Alzheimer’s disease, for whom cerebrovascular dysfunction can result in
compromised perfusion [78–80], there is limited evidence of vascular degeneration in FTD
patients beyond that typically attributed to age [77]. In the absence of a priori knowledge,
the current study used a PLD of 2 s, based on the recommendations of the ASL white paper
[29]. Although some studies have shown increased sensitivity by correcting for transit
times [81], on average, less than 4.2 ± 4.4% of transit times measured in the current study
were greater than the selected PLD. When ATT values greater than 2.3 s were considered,
this value dropped to 0.8 ± 0.9%. These results are in agreement with Dai et al. who
reported that a PLD between 2 to 2.3 s is sufficient for imaging elderly cohorts [27]. Given
that intensity normalization further diminishes the need for ATT correction [27] and yields
greater reproducibility and reliability [70], a PLD of 2 s is sufficient for SD-pCASL
imaging of FTD patients. This is particularly encouraging for studies focused on assessing
presymptomatic perfusion changes considering the effects of ATT should be even more
muted due to the younger age of the participants.
While single delay pCASL with a 3D readout is currently recommended for ASL
perfusion imaging [29], novel Hadamard encoded approaches are gaining interest due to
their ability to image both CBF and ATT in a similar amount of time with good spatial
resolution and SNR [30,31,82]. Of note, FL_TE-pCASL offers the benefit of acquiring
both perfusion and transit time images with similar PLD and LD as the single delay
sequence, but without an increase in scan time [83,84]. While visual inspection revealed
greater agreement between FL_TE-pCASL and SD-pCASL, both Hadamard-encoded
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sequences showed increased contrast in the basal ganglia and insula, compared to SDpCASL (Figure 4.5). This difference could be attributed to z-direction blurring, a welldocumented artifact associated with GRASE readout, as well as differences in labeling
parameters between the sequences [85]. Hadamard-based perfusion were not significantly
different from SD-pCASL in the occipital gyrus. This reduced perfusion is in line with the
superior posterior watershed region that experiences longer ATTs and, furthermore,
inspection of perfusion maps revealed hyperperfusion where the vessels enter the cerebrum
(e.g. the circle of Willis), particularly with conv_TE-pCASL. Hadamard encoded
sequences produced significantly higher CBF estimates relative to SD-pCASL (Figure
4.6). To date, few studies have performed a head-to-head comparison of these sequences
and no studies in older populations. A recent study demonstrated that CBF by conv_TEpCASL was 22% higher perfusion in a population of young healthy participants [32].
Given that internal consistency is critical for longitudinal imaging, the good reproducibility
of conv_TE-pCASL (CV= 10.5%, ICCbetween=0.77) over a 45 day period reported by Cohen
et al., highlights the potential for these novel sequences [81]. Furthermore, as demonstrated
by the results of this study, relative perfusion provides a stable estimate of perfusion over
time, making this systematic offset less concerning.
There are a number of limitations with the current study. First, the estimates of
variability were conducted with small sample sizes. Despite this, the results among patients
and controls were similar to each other as well as to previous studies. Considering that
different subtypes may have differing degrees of regional variability, future studies could
investigate subtype-specific sensitivities. Another consideration was the use of global CBF
for normalizing the perfusion images. Reference regions need to be selected carefully since
errors can be introduced if there are regional perfusion deficits that alter global CBF [86].
While the cerebellum is often used as a reference region, it is not always within the ASL
FOV, and furthermore, studies have identified cerebellar atrophy in some patients with
FTD [87,88]. Since there was no difference in global perfusion between patients and
controls, global CBF was chosen as a suitable reference region. The low spatial resolution
compounded with regional brain atrophy in patient participants can lead to reduced
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perfusion due to partial volume errors. While the current study did not investigate the
influence of partial volume errors, previous work demonstrated that similar hypoperfusion
patterns were detected without partial volume correction applied [89]. More importantly, a
between-session delay of 4 weeks was chosen to avoid any atrophy-driven perfusion
changes between sessions. Finally, although efforts were made to select optimal labeling
and bolus/sub-bolus durations among the ASL sequences being compared, it is evident that
the Hadamard encoded sequences could have been further optimized (e.g. increasing the
sub-bolus durations and PLD) to reduce the effects of vascular signal [85].

4.5 Conclusion
The results of the current study indicate that SD-pCASL with the appropriate labeling
parameters is a promising approach for assessing longitudinal changes in CBF associated
with FTD. With the current implementation, it was predicted that ASL can reliably detect
changes in perfusion as small as 10% with an estimated sample size of 10 patients with
relative perfusion. Agreement of longitudinal measures of CBF and ATT were similar in
patients and controls, indicating that there was no additional source of variability with FTD
patients compared to age-matched controls. Relative to Hadamard-encoded sequences, SDpCASL showed better grey-to-white matter contrast; however, Hadamard-encoded ASL
showed better contrast in the deep-brain regions. While the current study assessed the
variability of perfusion measurements within-subject, another important aspect in the
diagnosis of FTD is the ability to assess differences between patients and controls. Future
work could evaluate the sensitivity of ASL for detecting disease-driven perfusion changes
by direct comparison to the gold standard, PET with radiolabeled water [90]. Additionally,
toward the ultimate goal of assessing longitudinal perfusion changes, methodologies
described in the current study could be implemented in large multi-centre studies to gain
greater insight into the potential clinical role of ASL in diagnosis and management of FTD.
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Supplemental Figures

S Figure 4.1: Regional between-session reproducibility (coefficient of
variation) of arterial transit times in controls and patients.
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Chapter 5
Conclusions and Future Directions

5

5.1 Thesis Summary
FTD is a debilitating neurodegenerative disease with no known cure. Recent
advancements in potential symptomatic and disease modifying therapies, highlight the
need for biomarkers to distinguish FTD subtypes and evaluate the efficacy of these novel
therapies. Given that perfusion is an early marker of neurodegeneration, ASL is an
attractive tool for studying the natural disease progression to identify clinical endpoints.
Ultimately, this could allow for earlier intervention, and provide a means to track changes
in response to novel therapies. However, inconsistent results across FTD studies highlight
the need to optimize ASL, particularly given that it is well known that the quality of the
CBF images are sensitive to the chosen labeling parameters. The objective of this thesis
was to explore the role of ASL in differential diagnosis and longitudinal monitoring of
FTD by evaluating its sensitivity for detecting disease-related perfusion change and its
longitudinal reproducibility and reliability. In capitalizing on the unique features PET/MR
imaging, most notably the ability to simultaneously acquire PET- and MRI-based perfusion
images, this thesis demonstrates the utility of ASL and supports its use as a biomarker in
FTD.

5.2 Chapter Findings
5.2.1

A Non-invasive Method for Quantifying Cerebral Blood Flow
by Hybrid PET/MR

Although 15O-water is considered the gold standard for imaging brain perfusion in
humans, quantitative imaging requires measuring the AIF, which involves an invasive and
technically demanding procedure, making it suboptimal for clinical populations including
FTD patients. To address this challenge, Chapter 2 describes a non-invasive hybrid
PET/MR approach (PMRFlow) for quantifying perfusion. Using a porcine model, CBF
was measured by an established, but invasive, PET method and compared to CBF maps
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generated by PMRFlow. Excellent agreement (R = 0.98) between the two methods was
found over a flow range from 30 to 100 ml/100g/min. These experiments confirmed the
accuracy of this non-invasive PET/MR method, which is important for CBF quantification
in patient populations for whom arterial catherization to measure the AIF can be
challenging.

5.2.2

Concordance of Regional Hypoperfusion by pCASL MRI and
15
O-water PET in Frontotemporal Dementia: Is pCASL an
Efficacious Alternative?

Given that the accuracy of ASL CBF can be affected by the choice of labeling
parameters, the objective of Chapter 3 was to evaluate the sensitivity of ASL to identify
regional perfusion deficits in individuals with FTD. In contrast to previous studies that
compared ASL to FDG-PET, a head-to-head comparison of CBF images was performed
against 15O-water-PET. PMRFlow (Chapter 2) was implemented to quantify CBF. Similar
patterns of hypoperfusion were identified by ASL and

15

O-water (sensitivity = 70%,

specificity = 78%). The majority of clusters identified by ASL were either overlapping
(43.4 ± 21.3%) or adjacent (50 ± 21.8%) to those identified by

15

O-water. Additionally,

regions of significant hypoperfusion were identified in regions commonly associated with
each FTD subtype/PSP. Although relative perfusion can be used to minimize betweensubject variability, the results demonstrated that care must be taken when selecting a
reference region to avoid potential bias. Altogether, these results support the use of ASL
for assessing regional perfusion deficits associated with neurodegeneration.

5.2.3

Sensitivity of Arterial Spin Labeling for Characterization of
Longitudinal Perfusion Changes in Frontotemporal Dementia
and Related Disorders

The sensitivity of ASL for detecting longitudinal changes in perfusion will depend
on the variability in resting perfusion across imaging sessions. To assess this, Chapter 4
presents the reproducibility and reliability of CBF images acquired from two sessions
separated by one month. Experiments involved both FTD patients and healthy controls. In
addition, the influence of ATT on the variability in CBF was evaluated. There was good
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agreement between grey-matter CBF measurements separated by a month in both patients
(CV=16.3%, ICC = 0.62) and controls (13.9%, ICC = 0.62). For a given participant,
typically less than 5% of voxels had ATT greater than the chosen PLD of 2 s, suggesting
that ATT is not a significant source of error with this patient population. Power analysis
(detection power =80%, and  = 0.05) revealed that ASL has the sensitivity to detect
perfusion changes as small as 10% with as few as 10 patients. These results highlight the
sensitivity of ASL for detecting longitudinal changes in perfusion.

5.3 Clinical Implications
Imaging methods are increasingly being used in drug discovery and longitudinal
monitoring of disease progression. Hybrid PET/MR imaging is emerging as a powerful
tool for understanding disorders due to the complementary strengths offered by the
individual modalities. Specifically, the molecular specificity of PET and soft tissue contrast
of MRI. In Chapter 2, I capitalized on another unique feature of PET/MRI, the ability to
simultaneously acquire

15

O-water and PC data to develop and validate a non-invasive

approach for perfusion imaging. While this approach was validated in a large animal
model, PMRFlow can be implemented as an alternative to the PET-only approach in
clinical populations for whom quantitative perfusion imaging is challenging. For example,
in Chapter 3, this approach was applied to evaluate the sensitivity of ASL for detecting
perfusion change in FTD. Additionally, Ishii et al. implemented an analogous approach for
quantifying CBF and cerebrovascular reserve in patients with cerebrovascular disease [1].
Ideally, clinical intervention should take place during the preclinical stage, when
pathological damage is minimal and potentially reversible. Attributed to the observation
that CBF and glucose metabolism change early in pathological aging, these physiological
measures have been identified as potential targets for evaluating disease progression and
predicting the clinical course [2,3]. Although FDG-PET is central to clinical assessment of
FTD, I demonstrated in this thesis the potential of perfusion imaging by ASL. In Chapter
3, I evaluated the ability of ASL to detect regional perfusion deficits. Previous studies were
limited to comparisons of regional hypoperfusion by ASL to hypometabolism by FDG-
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PET in a one or two FTD-subtypes [4–10]. In addition, many of these studies used varying
ASL imaging parameters, which contributed to the variable findings with regard to the
sensitivity of ASL. I expanded the current knowledge by: (1) evaluating the sensitivity of
an optimized ASL sequence by performing a head-to-head comparison to 15O-water PET,
and (2) evaluating regional perfusion changes across a heterogeneous sample of FTD
patients. The results illustrated that regional perfusion deficits identified by ASL in patients
with FTD and PSP were comparable to those identified by 15O-water and, furthermore, that
ASL could detect regional perfusion deficits associated with each FTD subtypes.
As an extension to the findings of Chapter 3, I demonstrated in Chapter 4 the
sensitivity of ASL for detecting longitudinal perfusion changes. While cross-sectional
studies, which make up the bulk of studies on neurodegeneration, provide valuable insights
into differences between patients and controls, longitudinal studies allow for the
assessment of perfusion changes throughout the disease process [2,11]. This provides a
means for tracking disease progression and evaluating the efficacy of candidate therapies.
By quantifying both the within and between-session variances, I showed (1) good stability
of repeat perfusion measurements in patients and controls (within-session CV = 19.2% and
16.2%, respectively), which can be improved with intensity normalization (within-session
CV = 16.3% and 13.9%, respectively), and (2) that for a 5-minute scan, within-session
variance is a dominant contribution to the overall within-subject variance. The latter
indicates that the recommended 5-minute scan [12] is not sufficient to accurately
characterize perfusion in this clinical population.

5.4 Future Directions
The work presented in this thesis provides a framework for further investigations of
longitudinal perfusion imaging by ASL. The methodologies explored in this thesis can be
expanded in various ways.
The studies presented in this thesis focus on symptomatic FTD/PSP. Considering that
the presymptomatic phase is when patients are most responsive to therapy and neurological
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damage is potentially reversible, it would be valuable to explore perfusion changes in
presymptomatic mutation carriers. In a cross-sectional study, Mutsaerts et al. demonstrated
that differences in ASL CBF between mutation-carriers and non-carriers were apparent
approximately 12.5 years prior to the expected age of symptom onset [13]. As
demonstrated by Dopper et al., the ability to evaluate longitudinal CBF changes among
presymptomatic FTD mutation-carriers provides insight into regions affected early in the
disease processes [14]. In a longitudinal study spanning 2 years, they demonstrated that
presymptomatic mutation carriers (n = 34) showed significant decline in CBF in
decrease frontal, temporal, parietal, and subcortical areas. Furthermore, mutation carriers
that converted to clinical FTD showed a greater reduction CBF. These findings, indicate
that there is a clear benefit to larger scale studies to further elucidate mutation-specific
changes. This would enable the identification of individuals at high-risk of developing
dementia and provide improved methods for stratification of subtypes.
In Chapter 3 and Chapter 4, I demonstrate the value of ASL in differential diagnosis
and longitudinal monitoring of FTD. However, I believe that for a more wholistic
understanding of FTD, a multifaceted solution is required. Previous cross-sectional studies
suggest a pathophysiological cascade of events that involves changes in neuroimaging,
cognition, blood and cerebrospinal fluid biomarkers [14–16]. Efforts to predict disease
progression based on these changes are underway. De Vis et al. evaluated the predictive
power of baseline perfusion for measures of cognition separated by 4 years in young (n =
101) and elderly (n = 115) participants [17]. In elderly participants, perfusion in the frontal
lobe, medial frontal cortex, and anterior cingulate cortex were significant predictors followup cognition. This relationship was not significant in younger participants, suggesting that
in young participants, changes in CBF are related to physiological noise whereas in elderly
they reflect cognitive decline. Staffaroni et al. extended this idea by investigating the
relationship between longitudinal changes in CBF, grey-matter volume, white-matter
hyperintensity, white-matter microstructure integrity, and cognitive decline in 136 elderly
participants [2]. Reductions in grey-matter perfusion were associated with greater
deterioration of brain structure and with declines in cognitive processing speed. Such
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studies emphasize the relationship between perfusion, cognition, and brain structure in
elderly populations and provide further evidence of the utility of ASL for understanding
neurodegeneration. In order to better understand the cascade of events leading to
neurodegeneration, it would be valuable to explore how longitudinal decreases in perfusion
relate to other markers of degeneration (e.g. changes in grey-matter volume loss, fluid
biomarker concentration, etc.). These could help to advance our understanding of the
disease process and more importantly allow for earlier diagnosis.
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